

Common and rare variant association analyses in Amyotrophic Lateral Sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

Authors

Wouter van Rheenen^{1,*,@}, Rick A.A. van der Spek^{1,*,#}, Mark K. Bakker^{1,*,#}, Joke J.F.A. van Vugt¹, Paul J. Hop¹, Ramona A.J. Zwamborn¹, Niek de Klein², Harm-Jan Westra², Olivier B. Bakker², Patrick Deelen^{2,3}, Gemma Shireby⁴, Eilis Hannon⁴, Matthieu Moisse^{5,6,7}, Denis Baird^{8,9}, Restuadi Restuadi¹⁰, Egor Dolzhenko¹¹, Annelot M. Dekker¹, Klara Gawor¹, Henk-Jan Westeneng¹, Gijs H.P. Tazelaar¹, Kristel R. van Eijk¹, Maarten Kooyman¹, Ross P. Byrne¹², Mark Doherty¹², Mark Heverin¹³, Ahmad Al Khleifat¹⁴, Alfredo Iacoangeli^{14,15,16}, Aleksey Shatunov¹⁴, Nicola Ticozzi^{17,18}, Johnathan Cooper-Knock¹⁹, Bradley N. Smith¹⁴, Marta Gromicho²⁰, Siddharthan Chandran^{21,22}, Suvankar Pal^{21,22}, Karen E. Morrison²³, Pamela J. Shaw¹⁹, John Hardy²⁴, Richard W. Orrell²⁵, Michael Sendtner²⁶, Thomas Meyer²⁷, Nazli Başak²⁸, Anneke J. van der Kooij²⁹, Antonia Ratti^{17,30}, Isabella Fogh¹⁴, Cinzia Gellera³¹, Giuseppe Lauria Pinter^{32,33}, Stefania Corti^{34,18}, Cristina Cereda³⁵, Daisy Sproviero³⁵, Sandra D'Alfonso³⁶, Gianni Soraru³⁷, Gabriele Siciliano³⁸, Massimiliano Filosto³⁹, Alessandro Padovani³⁹, Adriano Chiò^{40,41}, Andrea Calvo^{40,41}, Cristina Moglia^{40,41}, Maura Brunetti⁴⁰, Antonio Canosa^{40,41}, Maurizio Grassano⁴⁰, Ettore Beghi⁴², Elisabetta Pupillo⁴², Giancarlo Logroscino⁴³, Beatrice Nefussy⁴⁴, Alma Osmanovic⁴⁵, Angelica Nordin⁴⁶, Yossef Lerner^{47,48}, Michal Zabari^{47,48}, Marc Gotkine^{47,48}, Robert H. Baloh^{49,50}, Shaughn Bell^{49,50}, Patrick Vourc'h^{51,52}, Philippe Corcia^{53,52}, Philippe Couratier^{54,55}, Stéphanie Millecamps⁵⁶, Vincent Meininger⁵⁷, François Salachas^{58,56}, Jesus S. Mora Pardina⁵⁹, Abdelilah Assialioui⁶⁰, Ricardo Rojas-García⁶¹, Patrick Dion⁶², Jay P. Ross^{62,63}, Albert C. Ludolph⁶⁴, Jochen H. Weishaupt⁶⁵, David Brenner⁶⁵, Axel Freischmidt^{64,66}, Gilbert Bensimon⁶⁷, Alexis Brice^{68,69,70}, Alexandra Dürr⁷¹, Christine A.M. Payan⁶⁷, Safa Saker-Delye⁷², Nicholas Wood⁷³, Simon Topp¹⁴, Rosa Rademakers⁷⁴, Lukas Tittmann⁷⁵, Wolfgang Lieb⁷⁵, Andre Franke⁷⁶, Stephan Ripke^{77,78,79}, Alice Braun⁷⁹, Julia Kraft⁷⁹, David C. Whiteman⁸⁰, Catherine M. Olsen⁸⁰, Andre G. Uitterlinden^{81,82}, Albert Hofman⁸², Marcella Rietschel⁸³, Sven Cichon^{84,85,86,87}, Markus M. Nöthen^{84,85}, Philippe Amouyel⁸⁸, SLALOM Consortium*, PARALS Consortium*, SLAGEN Consortium*, SLAP Consortium*, Bryan Traynor^{89,90}, Adrew B. Singleton⁹¹, Miguel Mitne Neto⁹², Ruben J. Cauchi⁹³, Roel A. Ophoff^{94,95,96}, Martina Wiedau-Pazos⁹⁷, Catherine Lomen-Hoerth⁹⁸, Vivianna M. van Deerlin⁹⁹, Julian Grosskreutz¹⁰⁰, Annkathrin Rödiger¹⁰⁰, Nayana Gaur¹⁰⁰, Alexander Jörk¹⁰⁰, Tabea Barthel¹⁰⁰, Erik Theele¹⁰⁰, Benjamin Ilse¹⁰⁰, Beatrice Stubendorff¹⁰⁰, Otto W. Witte¹⁰⁰, Robert Steinbach¹⁰⁰, Christian A. Hübner¹⁰¹, Caroline Graff¹⁰², Lev Brylev^{103,104,105}, Vera Fominykh^{103,105}, Vera Demeshonok¹⁰⁶, Anastasia Ataulina¹⁰³, Boris Rogelj^{107,108,109}, Blaž Koritnik¹¹⁰, Janez Zidar¹¹⁰, Metka Ravnik-Glavac¹¹¹, Damjan Glavac¹¹², Zorica Stevic¹¹³, Vivian Drory⁴⁴, Monica Povedano⁶⁰, Ian P. Blair¹¹⁴, Matthew C. Kiernan¹¹⁵, Beben Benyamin^{10,116}, Robert D. Henderson^{117,118,119}, Sarah Furlong¹¹⁴, Susan Mathers¹²⁰, Pamela A. McCombe^{117,121}, Merrilee Needham^{119,122,123}, Shyuan T. Ngo^{117,124,118}, Garth A. Nicholson¹¹⁴, Roger Pamphlett¹²⁵, Dominic B. Rowe¹¹⁴, Frederik J. Steyn^{126,121}, Kelly L. Williams¹¹⁴, Karen Mather^{127,128}, Perminder S. Sachdev^{127,129}, Anjali K. Henders¹⁰, Leanne Wallace¹⁰, Mamede de Carvalho²⁰, Susana Pinto²⁰, Susanne Petri⁴⁵, Alma Osmanovic⁴⁵, Markus Weber¹³⁰, Guy A. Rouleau⁶², Vincenzo Silani^{17,18}, Charles Curtis¹³¹, Jerome Breen^{132,133}, Jonathan Glass¹³⁴, Robert H. Brown¹³⁵, John E. Landers¹³⁵, Christopher E. Shaw¹⁴, Peter M. Andersen⁴⁶, Ewout J.N. Groen¹, Michael A.

van Es¹, R. Jeroen Pasterkamp¹³⁶, Dongsheng Fan¹³⁷, Fleur C. Garton¹⁰, Allan F. McRae¹⁰, George Davey Smith^{9,138}, Tom R. Gaunt^{9,138}, Michael A. Eberle¹¹, Jonathan Mill⁴, Russell L. McLaughlin¹², Orla Hardiman¹³, Kevin P. Kenna^{136,1}, Naomi R. Wray^{10,117}, Ellen Tsai⁸, Heiko Runz⁸, Lude Franke², Ammar Al-Chalabi^{14,139}, Philip Van Damme^{5,6,7}, Leonard H. van den Berg^{1,*} & Jan H. Veldink^{1,*,@}

Affiliations

1: Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

2: Department of Genetics, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.

3: Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

4: University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.

5: KU Leuven – University of Leuven, Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute (LBI), Leuven, Belgium.

6: VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium.

7: University Hospitals Leuven, Department of Neurology, Leuven, Belgium.

8: Translational Biology, Biogen, Boston, Massachusetts, USA.

9: MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, University of Bristol, Bristol, UK.

10: Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.

11: Illumina, San Diego, California, USA.

12: Complex Trait Genomics Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin D02 PN40, Ireland.

13: Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin D02 PN40, Ireland.

14: Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

15: Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

16: National Institute for Health Research Biomedical Research Centre and Dementia Unit, South London and Maudsley NHS Foundation Trust and King's College London, London, UK.

17: Department of Neurology-Stroke Unit and Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milan, Italy.

- 18: Department of Pathophysiology and Transplantation, “Dino Ferrari” Center, Università degli Studi di Milano, Milan, Italy.
- 19: Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
- 20: Instituto de Fisiologia, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
- 21: Euan MacDonald Centre for Motor Neurone Disease Research, Edinburgh, UK.
- 22: Centre for Neuroregeneration and Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK.
- 23: School of Medicine, Dentistry, and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
- 24: Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
- 25: Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
- 26: Institute of Clinical Neurobiology, University Hospital Würzburg, Würzburg, Germany.
- 27: Charité University Hospital, Humboldt-University, Berlin, Germany.
- 28: Neurodegeneration Research Laboratory, Bogazici University, Istanbul, Turkey.
- 29: Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands.
- 30: Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy.
- 31: Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.
- 32: 3rd Neurology Unit, Motor Neuron Diseases Center, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.
- 33: ‘L. Sacco’ Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy.
- 34: Neurology Unit, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- 35: Genomic and Post-Genomic Center, IRCCS Mondino Foundation, Pavia, Italy.
- 36: Department of Health Sciences, University of Eastern Piedmont, Novara, Italy.
- 37: Department of Neurosciences, University of Padova, Padova, Italy.
- 38: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- 39: Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

- 40: “Rita Levi Montalcini” Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.
- 41: Neurologia 1, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Turin, Italy.
- 42: Laboratory of Neurological Diseases, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
- 43: Department of Clinical Research in Neurology, University of Bari at “Pia Fondazione Card G. Panico” Hospital, Bari, Italy.
- 44: Department of Neurology, Tel-Aviv Sourasky Medical Centre, Tel-Aviv, Israel.
- 45: Department of Neurology, Hannover Medical School, Hannover, Germany.
- 46: Department of Clinical Sciences, Neurosciences, Umeå University, SE-901 85 Umeå, Sweden.
- 47: Faculty of Medicine, Hebrew University of Jerusalem, Israel.
- 48: The Agnes Ginges Center for Human Neurogenetics, Dept. of Neurology, Hadassah Medical Center, Jerusalem, Israel.
- 49: Center for Neural Science and Medicine, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA
- 50: Department of Neurology, Neuromuscular Division, Cedars-Sinai Medical Center, Los Angeles, California, 90048, USA.
- 51: Service de Biochimie et Biologie moléculaire, CHU de Tours, Tours, France.
- 52: UMR 1253, Université de Tours, Inserm, 37044 Tours, France.
- 53: Centre de référence sur la SLA, CHU de Tours, Tours, France.
- 54: Centre de référence sur la SLA, CHRU de Limoges, Limoges, France.
- 55: UMR 1094, Université de Limoges, Inserm, 87025 Limoges, France.
- 56: ICM, Institut du Cerveau, Inserm, CNRS, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.
- 57: Hôpital des Peupliers, Ramsay Générale de Santé, 75013 Paris, France.
- 58: Département de Neurologie, Centre de référence SLA Ile de France, Hôpital de la Pitié Salpêtrière, AP-HP, Paris, France.
- 59: ALS Unit, Hospital San Rafael, Madrid, Spain.
- 60: Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
- 61: MND Clinic, Neurology Department, Hospital de la Santa Creu i Sant Pau de Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.
- 62: Montreal Neurological Institute and Hospital, McGill University, Montréal H3A 2B4, Canada.

- 63: Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada.
- 64: Department of Neurology, Ulm University, Ulm, Germany.
- 65: Division of Neurodegeneration, Department of Neurology, University Medicine Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
- 66: German Center for Neurodegenerative Diseases (DZNE) Ulm, Ulm, Germany.
- 67: Département de Pharmacologie Clinique, Hôpital de la Pitié-Salpêtrière, UPMC Pharmacologie, AP-HP, Paris, France.
- 68: INSERM U289, Hôpital Salpêtrière, AP-HP, Paris, France.
- 69: Département de Génétique, Cytogénétique et Embryologie, Hôpital Salpêtrière, AP-HP, Paris, France.
- 70: Fédération de Neurologie, Hôpital Salpêtrière, AP-HP, Paris, France.
- 71: Department of Medical Genetics, L'Institut du Cerveau et de la Moelle Épinrière, Hôpital Salpêtrière, Paris, France.
- 72: Genethon, CNRS UMR, 8587 Evry, France.
- 73: Department of Neurogenetics, UCL Institute of Neurology, Queen Square, London, UK.
- 74: Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA.
- 75: Popgen Biobank and Institute of Epidemiology, Christian Albrechts-University Kiel, Kiel, Germany.
- 76: Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany.
- 77: Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
- 78: Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- 79: Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin, Berlin 10117, Germany.
- 80: Cancer Control Group, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
- 81: Department of Internal Medicine, Genetics Laboratory, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
- 82: Department of Epidemiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
- 83: Central Institute of Mental Health, Mannheim, Germany; Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.
- 84: Institute of Human Genetics, University of Bonn, Bonn, Germany.
- 85: Department of Genomics, Life and Brain Center, Bonn, Germany.

86: Division of Medical Genetics, University Hospital Basel and Department of Biomedicine, University of Basel, Basel, Switzerland.

87: Institute of Neuroscience and Medicine INM-1, Research Center Juelich, Juelich, Germany.

88: Univ. Lille, Inserm, Centre Hosp. Univ. Lille, Institut Pasteur de Lille, UMR1167 - RID-AGE LabEx DISTALZ - Risk factors and molecular determinants of aging-related diseases, F-59000 Lille, France.

89: Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, NIH, Porter Neuroscience Research Center, Bethesda, Maryland, USA

90: Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.

91: Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, NIH, Porter Neuroscience Research Center, Bethesda, Maryland, USA.

92: Universidade de São Paulo, São Paulo, Brazil.

93: Centre for Molecular Medicine and Biobanking & Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, Malta.

94: University Medical Center Utrecht, Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, The Netherlands

95: Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, California, USA.

96: Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, California, USA.

97: Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.

98: Department of Neurology, University of California, San Francisco, California, USA.

99: Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

100: Hans-Berger-Department of Neurology, Jena University Hospital, Jena, Germany.

101: Institute of Human Genetics, Jena University Hospital, Jena, Germany.

102: Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden.

103: Department of Neurology, Bujanov Moscow Clinical Hospital, Moscow, Russia.

104: Moscow Research and Clinical Center for Neuropsychiatry of the Healthcare Department, Moscow, Russia.

105: Department of Functional Biochemistry of the Nervous System, Institute of Higher Nervous Activity and Neurophysiology Russian Academy of Sciences, Moscow, Russia.

106: ALS-care center, "GAOORDI", Medical Clinic of the St. Petersburg, St. Petersburg, Russia.

- 107: Department of Biotechnology, Jožef Stefan Institute, Ljubljana, Slovenia.
- 108: Biomedical Research Institute BRIS, Ljubljana, Slovenia.
- 109: Faculty of Chemistry and Chemical Technology, Universtiy of Ljubljana, Ljubljana, Slovenia.
- 110: Ljubljana ALS Centre, Institute of Clinical Neurophysiology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
- 111: Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
- 112: Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
- 113: Clinic of Neurology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia
- 114: Centre for Motor Neuron Disease Research, Faculty of Medicine, Health and Human Sciences, Macquarie University, NSW 2109, Australia.
- 115: Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.
- 116: Australian Centre for Precision Health & Allied Health and Human Performance, University of South Australia, Adelaide, SA 5001 Australia.
- 117: Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia.
- 118: Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.
- 119: Fiona Stanley Hospital, Perth, WA 6150, Australia.
- 120: Calvary Health Care Bethlehem, Parkdale, VIC 3195, Australia.
- 121: Department of Neurology, Royal Brisbane and Women's Hospital, Brisbane, QLD 4029, Australia.
- 122: Notre Dame University, Fremantle, WA 6160, Australia.
- 123: Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA 6150, Australia.
- 124: The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia.
- 125: Discipline of Pathology and Department of Neuropathology, Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
- 126: The School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4074, Australia.
- 127: Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, NSW 2031, Australia.
- 128: Neuroscience Research Australia Institute, Randwick, NSW 2031, Australia.

129: Neuropsychiatric Institute, The Prince of Wales Hospital, UNSW, Randwick, NSW 2031, Australia.

130: Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, 9007, St. Gallen, Switzerland.

131: MRC Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK.

132: IoPPN Genomics & Biomarker Core, Translational Genetics Group, MRC Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK.

133: NIHR Biomedical Research Centre for Mental Health, Maudsley Hospital and Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

134: Department Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.

135: Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

136: Department of Translational Neuroscience, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

137: Department of Neurology, Peking University, Third Hospital, No. 49, North Garden Road, Haidian District, Beijing, 100191, China.

138: Population Health Science, Bristol Medical School, Bristol, Bristol BS8 1TH, UK.

139: King's College Hospital, Denmark Hill, SE5 9RS London, UK.

Shared first authors

+ Shared last authors

@ Corresponding authors

* A list of authors and their affiliations appears at the end of the paper.

Correspondence

Wouter van Rheenen: w.vanrheenen-2@umcutrecht.nl

Jan H. Veldink: j.h.veldink@umcutrecht.nl

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a life-time risk of 1 in 350 people and an unmet need for disease-modifying therapies. We conducted a cross-ancestry GWAS in ALS including 29,612 ALS patients and 122,656 controls which identified 15 risk loci in ALS. When combined with 8,953 whole-genome sequenced individuals (6,538 ALS patients, 2,415 controls) and the largest cortex-derived eQTL dataset (MetaBrain), analyses revealed locus-specific genetic architectures in which we prioritized genes either through rare variants, repeat expansions or regulatory effects. ALS associated risk loci were shared with multiple traits within the neurodegenerative spectrum, but with distinct enrichment patterns across brain regions and cell-types. Across environmental and life-style risk factors obtained from literature, Mendelian randomization analyses indicated a causal role for high cholesterol levels. All ALS associated signals combined reveal a role for perturbations in vesicle mediated transport and autophagy, and provide evidence for cell-autonomous disease initiation in glutamatergic neurons.

Introduction

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting 1 in 350 individuals. Due to degeneration of both upper and lower motor neurons patients suffer from progressive paralysis, ultimately leading to respiratory failure within three to five years after disease onset.¹ In ~10% of ALS patients there is a clear family history for ALS suggesting a strong genetic predisposition and currently in more than half of these cases a pathogenic mutation can be found.² On the other hand, apparently sporadic ALS is considered a complex trait where heritability is estimated at 40-50%.^{3,4} To date, partially overlapping GWASs have identified up to six genome-wide significant loci, explaining a small proportion of the genetic susceptibility to ALS.⁵⁻¹⁰ Some of these loci found in GWAS harbor rare variants with large effects also present in familial cases (e.g. *C9orf72* and *TBK1*).¹¹⁻¹³ For other loci, the role of rare variants remains unknown.

While ALS is referred to as a motor neuron disease, cognitive and behavioral changes are observed in up to 50% of the patients, sometimes leading to frontotemporal dementia (FTD). The overlap with FTD is clearly illustrated by the pathogenic hexanucleotide repeat expansion in *C9orf72* which causes familial ALS and/or FTD^{11,12} and the genome-wide genetic correlation between ALS and FTD.¹⁴ Further expanding the ALS/FTD spectrum, a genetic correlation with progressive supranuclear palsy has been described.¹⁵ Shared pathogenic mechanisms between ALS and other neurodegenerative diseases, including common diseases such as Alzheimer's and Parkinson's disease, can further reveal ALS pathophysiology and inform new therapeutic strategies.

Here, we combine new and existing individual level-genotype data in the largest GWAS of ALS to date. We present a comprehensive screen for pathogenic rare variants and short tandem repeat (STR) expansions as well as regulatory effects observed in brain cortex-derived RNA-seq and methylation datasets to prioritize causal genes within ALS risk loci. Furthermore, we reveal similarities and differences between ALS and other neurodegenerative diseases as well as the biological processes in disease-relevant tissues and cell-types that affect ALS risk.

Results

Cross-ancestry meta-analysis reveals 15 risk loci for ALS. To generate the largest genome-wide association study in ALS to date, we merged individual level genotype data from 117 cohorts into 6 strata matched by genotyping platform. A total of 27,205 ALS patients and 110,881 control subjects of European ancestries passed quality control (**Online Methods, Supplementary Table 1-2**). Through meta-analysis of these six strata, we obtained association statistics for 10,461,755 variants down to an observed minor allele-frequency of 0.1% in the Haplotype Reference Consortium resource¹⁶. We observed moderate inflation of the test statistics ($\lambda_{GC} = 1.12$, $\lambda_{1000} = 1.003$) and linkage-disequilibrium score regression yielded an intercept of 1.029 (SE = 0.0073), indicating that the majority of inflation is due to the polygenic signal in ALS. The European ancestries analysis identified 12 loci reaching genome-wide significance ($P < 5.0 \times 10^{-8}$, **Supplementary Figure 1**). Of these, 8 were present in GWAS of ALS in Asian ancestries^{8,10} and all showed a consistent direction of effects ($P_{\text{binom}} = 3.9 \times 10^{-3}$). The genetic overlap between ALS risk in European and Asian ancestries resulted in a trans-ancestry genetic correlation of 0.57 (SE = 0.28) for genetic effect and 0.58 (SE = 0.30) for genetic impact, which were not statistically significant different from unity ($P = 0.13$ and 0.16 , respectively). We therefore performed a cross-ancestry meta-analysis which revealed three additional loci, totaling 15 genome-wide significant risk loci for ALS risk (**Figure 1, Table 1, Supplementary Figures 2-16, Supplementary Tables 4-18**). Conditional and joint analysis did not identify secondary signals within these loci.

Of these findings, 8 loci have been reported in previous genome-wide association studies (*C9orf72*, *UNC13A*, *SCFD1*, *MOBP/RPSA*, *KIF5A*, *CFAP410*, *GPX3/TNIP1*, and *TBK1*)⁷⁻⁹. The rs80265967 variant corresponds to the p.D90A variant in *SOD1* previously identified in a Finnish ALS cohort enriched for familial ALS⁶. Interestingly, we observed for the first time, a genome-wide significant common variant association signal within the *NEK1* locus, where *NEK1* was previously shown to harbor rare variants associated with ALS¹⁷. The recently reported association at the *ACSL5-ZDHHC6* locus^{10,18} did not reach the threshold for genome-wide significance (rs58854276, $P_{\text{EUR}} = 5.4 \times 10^{-5}$, $P_{\text{ASN}} = 4.9 \times 10^{-7}$, $P_{\text{comb}} = 6.5 \times 10^{-8}$, **Supplementary Figure 17, Supplementary Table 19**), despite that our analysis includes all data from the original discovery studies.




Figure 1. Manhattan plot of cross-ancestry meta-analysis. Horizontal dotted line reflects threshold for calling SNPs genome-wide significant ($P = 5 \times 10^{-8}$). Gene labels reflect those prioritized by gene prioritization analysis.

Chr	Basepair	ID	Prioritized gene	A1	A2	Freq	European ancestries		Asian ancestries		Cross-ancestry	
							Effect (SE)	P	Effect (SE)	P	Effect (SE)	P
9	27563868	rs2453555	<i>C9orf72</i>	A	G	0.248	0.174 (0.013)	1.0×10^{-43}	0.017 (0.066)	0.80	0.168 (0.012)	1.5×10^{-41}
19	17752689	rs12608932	<i>UNC13A</i>	C	A	0.347	0.125 (0.012)	8.8×10^{-25}	0.074 (0.038)	0.053	0.120 (0.012)	3.0×10^{-25}
21	33039603	rs80265967	<i>SOD1</i>	C	A	0.006	1.078 (0.124)	3.5×10^{-18}	-	-	1.078 (0.124)	3.5×10^{-18}
14	31045596	rs229195	<i>SCFD1</i>	A	G	0.337	0.091 (0.012)	9.2×10^{-15}	-	-	0.091 (0.012)	9.2×10^{-15}
3	39508968	rs631312	<i>MOBP/RPSA</i>	G	A	0.291	0.079 (0.012)	5.2×10^{-11}	0.084 (0.036)	0.020	0.080 (0.011)	3.3×10^{-12}
6	32672641	rs9275477	<i>HLA</i>	C	A	0.096	-0.143 (0.021)	5.5×10^{-12}	-0.110 (0.111)	0.32	-0.142 (0.02)	3.5×10^{-12}
12	57975700	rs113247976	<i>KIF5A</i>	T	A	0.016	0.332 (0.049)	1.4×10^{-11}	-	-	0.332 (0.049)	1.4×10^{-11}
21	45753117	rs75087725	<i>CFAP410</i>	A	C	0.012	0.418 (0.063)	2.7×10^{-11}	-	-	0.418 (0.063)	2.7×10^{-11}
5	150410835	rs10463311	<i>GPX3/TNIP1</i>	C	T	0.253	0.079 (0.013)	3.5×10^{-10}	0.042 (0.036)	0.24	0.075 (0.012)	2.7×10^{-10}
20	48438761	rs17785991	<i>SLC9A8/SPATA2</i>	A	T	0.353	0.074 (0.012)	3.5×10^{-10}	0.045 (0.076)	0.55	0.073 (0.012)	3.2×10^{-10}
12	64877053	rs4075094	<i>TBK1</i>	A	T	0.112	-0.098 (0.018)	1.7×10^{-8}	-0.216 (0.090)	0.017	-0.103 (0.017)	2.1×10^{-9}
5	172354731	rs517339	<i>ERGIC1</i>	C	T	0.397	-0.065 (0.011)	8.5×10^{-9}	-0.067 (0.074)	0.37	-0.065 (0.011)	5.6×10^{-9}
4	170583157	rs62333164	<i>NEK1</i>	G	A	0.335	0.063 (0.012)	7.0×10^{-8}	0.203 (0.070)	3.8×10^{-3}	0.067 (0.012)	6.9×10^{-9}
13	46113984	rs2985994	<i>COG3</i>	C	T	0.259	0.066 (0.013)	1.9×10^{-7}	0.100 (0.041)	0.014	0.069 (0.012)	1.2×10^{-8}
7	157481780	rs10280711	<i>PTPRN2</i>	G	C	0.124	0.076 (0.017)	5.8×10^{-6}	0.132 (0.037)	2.9×10^{-4}	0.086 (0.015)	1.8×10^{-8}

Table 1. Genome-wide significant loci. Details of the top associated SNPs within each genome-wide significant locus. Chr = chromosome, Basepair = position in reference genome GRCh37, A1 = effect allele, A2 = non-effect allele, Freq = frequency of the effect allele in European ancestries GWAS, SE = standard error of effect estimate.

Rare variant association analyses in ALS. To assess a general pattern of underlying architectures that link associated SNPs to causal genes we first tested for annotation specific enrichment using stratified linkage disequilibrium score regression (LDSC). This revealed that 5' UTR regions as well as coding regions in the genome and those annotated as conserved were most enriched for ALS-associated SNPs (**Supplementary figure 18**). Subsequently we investigated how rare, coding variants contributed to ALS risk generating a whole-genome sequencing dataset of ALS patients (N = 6,538) and controls (N = 2,415). The exome-wide association analysis included transcript-level rare-variant burden testing for different models of allele-frequency thresholds and variant annotations (**Online methods**). This identified *NEK1* as the strongest associated gene (minimal $P = 4.9 \times 10^{-8}$ for disruptive and damaging variants at minor allele frequency [MAF] < 0.005), which was the only gene to pass the exome-wide significance thresholds ($0.05/17,994 = 2.8 \times 10^{-6}$ and $0.05/58,058 = 8.6 \times 10^{-7}$ for number of genes and protein-coding transcripts, respectively, **Supplementary figures 19-32**). This association is independent from the previously reported increased rare variant burden in familial ALS patients¹⁷ that were not included in this study.

Gene prioritization shows locus-specific underlying architectures. To assess whether rare variant associations could drive the common variant signals at the 15 genome-wide significant loci, we combined the common and rare variants analyses to prioritize genes within these loci. The SNP effects on gene expression were assessed through summary-based Mendelian Randomization (SMR) in blood (eQTLGen¹⁹) and a new brain cortex-derived expression quantitative trait locus (eQTL) dataset (MetaBrain²⁰). Similarly, we analyzed methylation-QTL (mQTL) through SMR in blood and brain-derived mQTL datasets²¹⁻²³. Finally, we leveraged the genome-wide signature of ALS associated gene features in a new gene prioritization method to calculate a polygenic priority score (PoPS)²⁴. Through these multi-layered gene prioritization strategies we classified each locus into one of four classes of most likely underlying genetic architecture to prioritize the causal gene (**Supplementary figures 33-47**).

First, in three GWAS loci the strongest associated SNP was a low-frequency coding variant which was nominated as the causal variant. This is the case for rs80265967 (*SOD1*, p.D90A, **Supplementary Figure 46**) and rs113247976 (*KIF5A* p.P986L, **Supplementary Figure 40**) which are coding variants in known ALS risk genes. This is also the most likely causal mechanism for rs75087725 (*CFAP410*, formerly *C21orf2*, p.V58L, **Supplementary Figure 46**) as the GWAS variant is coding, no evidence for other mechanisms including repeat expansions, eQTL or mQTL effects is observed within this locus, and *CFAP410* itself is known to directly interact with *NEK1*, another ALS gene.^{13,25} These three loci illustrate the power of large-scale GWAS combined with modern imputation panels to directly identify low-frequency causal variants that confer disease risk.

Second, SNPs can tag a highly pathogenic repeat expansion, as is seen for rs2453555 (*C9orf72*) and the known GGGGCC hexanucleotide repeat in this locus. Conditional analysis revealed no residual signal after conditioning on the repeat expansion which is in LD with the top-SNP ($r^2 = 0.14$, $|D'| = 0.99$, $MAF_{SNP} = 0.25$, $MAF_{STR} = 0.047$). Besides the repeat expansion, both eQTL and mQTL analysis point to *C9orf72* (**Supplementary Figure 39**). The HEIDI outlier test, however, rejected the null hypothesis that gene expression or methylation mediated the causal effect of the associated SNP ($P_{HEIDI_eQTL} = 3.7 \times 10^{-23}$ and $P_{HEIDI_mQTL} = 4.1 \times 10^{-7}$). This is in line with the pathogenic repeat expansion as the causal variant in this

locus as and that eQTL and mQTL effects do not mediate a causal effects. Across all other genome-wide significant loci, we found no similar repeat expansions that fully explain the SNP association signal.

Third, in two loci (rs62333164 in *NEK1* and rs4075094 in *TBK1*) common and rare variants converge to the same gene, which are known ALS risk genes^{13,17}. For both loci, the rare variant burden association is conditionally independent from the top SNP which was included in the GWAS (**Supplementary figures 34 and 41**). Here, the eQTL and mQTL analyses indicated that the risk-increasing effects of the common variants are mediated through both eQTL and mQTL effects on *NEK1* and *TBK1*. Furthermore, a polymorphic STR downstream of *NEK1* was associated with increased ALS risk (motif = TTAA, threshold = 10 repeat units, expanded allele-frequency = 0.51, $P = 5.2 \times 10^{-5}$, $FDR = 4.7 \times 10^{-4}$, **Supplementary figure 48**). This polymorphic repeat is in LD with the top associated SNP within this locus ($r^2 = 0.24$, $|D'| = 0.70$). Within the whole-genome sequencing data, there was no statistically significant association for the top SNP to reliably determine its independent contribution to ALS risk.

Lastly, the fourth group contains remaining loci where there is no direct link to a causal gene through coding variants or repeat expansions. Here, we investigated regulatory effects of the associated SNPs on target genes acting as either eQTL or mQTL. Across all loci, single genes were prioritized by SMR using both mQTL and eQTL for rs2985994 (*COG3* **Supplementary Figure 42**), rs229243 (*SCFD1*, **Supplementary Figure 43**), and rs517339 (*ERGIC1*, **Supplementary Figure 36**). In other loci, both methods prioritized multiple genes, such as rs631312 (*MOBP* and *RPSA*, **Supplementary Figure 33**) and rs10463311 (*GPX3* and *TNIP1*, **Supplementary Figure 35**). Besides the prioritized genes, each of these loci harbor multiple genes that are not prioritized by any method and are therefore less likely to contribute to ALS risk.

Locus-specific sharing of risk loci between ALS and neurodegenerative diseases. To investigate the pleiotropic properties of ALS-associated loci and shared genetic basis of neurodegeneration, we tested for shared effects among neurodegenerative diseases. We included GWAS from clinically-diagnosed Alzheimer's disease (AD)²⁶, Parkinson's disease (PD)²⁷, frontotemporal dementia (FTD)²⁸, progressive supranuclear palsy (PSP)¹⁵ and corticobasal degeneration (CBD)²⁹ to estimate genetic correlations across neurodegenerative diseases. Bivariate LDSC confirmed a statistically significant genetic correlation between ALS and PSP ($r_g = 0.44$, $SE = 0.11$, $P = 1.0 \times 10^{-4}$) as previously reported, and also found a significant genetic correlation between ALS and AD ($r_g = 0.31$, $SE = 0.12$, $P = 9.6 \times 10^{-3}$) as well as between ALS and PD ($r_g = 0.16$, $SE = 0.061$, $P = 0.011$, **Figure 2a**). The point estimate for the genetic correlation between ALS and FTD was high ($r_g = 0.59$, $SE = 0.41$, $P = 0.15$), but not statistically significant due to the limited size of the FTD GWAS. Thus, power to detect a genetic correlation between ALS and FTD using LDSC was limited (**Supplementary Figure 49**).

Patterns of sharing disease-associated genetic variants appeared to be locus specific (**Figure 2b**, **Supplementary Table 20**). To assess whether two traits shared a common signal indicating shared causal variants, we performed colocalization analyses for all loci meeting $P < 5 \times 10^{-5}$ in any of the GWAS on neurodegenerative diseases ($N = 161$ loci). This revealed a shared signal in the *MOBP/RPSA* between ALS, PSP and CBD, as well as a shared signal in the *UNC13A* locus between ALS and FTD (posterior probability: $PP_{H4} > 95\%$, **Supplementary Figure 50**). For the *HLA* locus, there was evidence for a shared causal variant

between ALS and PD ($PP_{H4} = 88\%$) but no conclusive evidence for ALS and AD ($PP_{H4} = 51\%$ for a shared causal variant and $PP_{H3} = 49\%$ for independent signals in both traits).

Furthermore, the colocalization analyses identified two additional shared loci that were not genome-wide significant in the ALS GWAS: between ALS and PD at the *GAK* locus (rs34311866, $PP_{H4} = 99\%$) and between ALS and AD at the *BRZAP-AS1* locus (rs2632516, $PP_{H4} = 90\%$). Of note, the association at *BRZAP-AS1* was not genome-wide significant in the GWAS of clinically diagnosed AD ($P = 3.7 \times 10^{-7}$) either, but was identified in the larger AD-by-proxy GWAS³⁰. For FTD subtypes, *C9orf72* showed a co-localization signal for a shared causal variant between ALS and the motor neuron disease subtype of FTD (mndFTD, $PP_{H4} = 93\%$, **Supplementary figure 50 and 51**).




Figure 2. Shared genetic risk among ALS and neurodegenerative diseases. (a) Genetic correlation analysis. Genetic correlation was estimated with LD-score regression between each pair of neurodegenerative diseases being ALS, Alzheimer's disease (AD), corticobasal degeneration (CBD), Parkinson's disease (PD), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). Lower left triangle shows correlation estimate and upper right triangle shows $-\log_{10}(P)$ -value. Correlations marked with an asterisk were statistically significant $P < 0.05$. **(b)** SNP associations of ALS lead SNPs or LD-proxies in neurodegenerative diseases. Effective sample size is shown on the left. Posterior probabilities of the same causal SNP affecting two diseases were estimated through colocalization analysis and highlighted as connections.

Enrichment of glutamatergic neurons indicate cell-autonomous processes in ALS susceptibility. To find tissues and cell-types which gene expression profiles are enriched for genes within ALS risk loci, we first combined gene-based association statistics calculated using MAGMA³¹ with gene expression patterns from GTEx (v8) in a gene-set enrichment analysis using FUMA.³² We observed a significant enrichment in genes expressed in brain tissues, specifically the cerebellum, basal ganglia (caudate nucleus, accumbens, and putamen), and cortex. Whereas this pattern roughly resembles the enrichments observed in PD, it is strikingly different from that observed in AD where blood, lung and spleen were mostly enriched (**Figure 3a**). We subsequently queried single-cell RNA sequencing datasets of human-derived brain samples to further specify brain-specific enriched cell-types using the cell-type analysis module in FUMA³³. This showed significant enrichment for neurons but not microglia or astrocytes (**Figure 3b**). Further subtyping of these neurons illustrated that genes expressed in glutamatergic neurons were mostly enriched for genes within the ALS-associated risk loci. Again, this contrasted AD which showed specific enrichment of microglia. In single-cell RNA sequencing data obtained from brain tissues in mice, a similar pattern was observed showing neuron-specific enrichment in ALS and PD, but microglia in AD (**Supplementary Figure**

52). Together, this indicates that susceptibility to neurodegeneration in ALS is mainly driven by neuron-specific pathology and not by immune-related tissues and microglia.




Figure 3. Tissue and cell-type enrichment analysis. (a) Enrichment of tissues and brain regions included in the GTEx v8 illustrates a brain-specific enrichment pattern in ALS, similar to Parkinson's disease but contrasting Alzheimer's disease. (b) Cell-type enrichment analyses indicate neuron-specific enrichment for glutamatergic neurons. No enrichment was found for microglia or other non-neuronal cell-types, contrasting the pattern observed in Alzheimer's disease. Statistically significant enrichment after correction for multiple testing with a false discovery rate (FDR) < 0.05 are marked with an asterisk. ALS = amyotrophic lateral sclerosis, PD = Parkinson's disease, AD = Alzheimer's disease, Cx = cortex, OPC = Oligodendrocyte progenitor cells.

Brain-specific co-expression networks improve ALS-relevant pathway detection. To assess which processes were mostly enriched in ALS, we performed enrichment analyses that combined gene-based association statistics with gene co-expression patterns obtained from either multi-tissue transcriptome datasets³⁴ or RNA-seq data from brain cortex samples (MetaBrain²⁰). To validate this approach, we first tested for enrichment of Human Phenotype Ontology (HPO) terms that are linked to well-established disease genes in the Online Mendelian Inheritance in Man (OMIM) and Orphanet catalogues. Using the multi-tissue co-expression matrix, we found no enriched HPO terms after Bonferroni correction for multiple testing. Using the brain-specific co-expression matrix however, we found a strong enrichment of HPO terms that are related to ALS or neurodegenerative diseases in general, including *Cerebral cortical atrophy* ($P = 1.8 \times 10^{-8}$), *Abnormal nervous system electrophysiology* ($P = 4.1 \times 10^{-7}$) and *Distal amyotrophy* (8.6×10^{-7} , full-list in **Supplementary table 21**). In general, HPO terms in the neurological branch (*Abnormality of the nervous system*) showed an increase in enrichment statistics in ALS when using the brain-specific co-expression matrix compared to the multi-tissue dataset (**Supplementary Figure 53**),

which illustrates the benefit of the brain-specific co-expression matrix for ALS-specific enrichment analyses. Subsequently, we tested for enriched biological processes using Reactome and Gene Ontology terms. Again, using the multi-tissue expression profiles, we found no Reactome annotations to be enriched. Leveraging the brain-specific co-expression networks we identified Vesicle Mediated Transport ("*Membrane Trafficking*" $P = 4.2 \times 10^{-6}$, "*Intra-golgi and retrograde Golgi-to-ER trafficking*" $P = 1.4 \times 10^{-5}$) and Autophagy ("*Macroautophagy*" $P = 3.2 \times 10^{-5}$) as enriched processes after Bonferroni correction for multiple testing (**Supplementary Table 22**). The enriched Gene Ontology terms all related to vesicle mediated transport or autophagy (**Supplementary Table 23 and 24**).

Cholesterol levels are causally related to ALS. From previous observational case-control studies and our accompanying blood-based methylome-wide study³⁵, numerous non-genetic risk factors have been implicated in ALS. Here we studied a selection of those putative risk factors through causal inference in a Mendelian randomization (MR) framework.³⁶ We selected 22 risk factors for which robust genetic predictors were available including BMI, smoking, alcohol consumption, physical activity, cholesterol-related traits, cardiovascular diseases and inflammatory markers (**Supplementary Table 25**). These analyses provided the strongest evidence for cholesterol levels causally related to ALS risk ($P_{\text{WeightedMedian}} = 3.2 \times 10^{-4}$, **Figure 4a**, full results in **Supplementary Table 26**). These results were robust to removal of outliers through Radial MR analysis³⁷ and we observed no evidence for reverse causality (**Supplementary Table 27 and 28**). Importantly, ascertainment bias can lead to the selection of higher educated control subjects³⁸, compared to ALS patients that are mostly ascertained through the clinic. In line with control subjects being longer educated, MR analyses indicate a negative effect for years of schooling on ALS risk ($P_{\text{IVW}} = 2.0 \times 10^{-4}$, **Figure 4b**). As a result, years of schooling can act as a confounder for the observed risk increasing effect of higher total cholesterol through ascertainment bias. To correct for this potential confounding, we applied multivariate MR analyses including both years of schooling and total cholesterol. The results for total cholesterol were robust in the multivariate analyses, suggesting a causal role for total cholesterol levels on ALS susceptibility (**Supplementary Table 29**).




Figure 4. Causal inference of total cholesterol and years of schooling in ALS. (a) Mendelian randomization results for ALS and total cholesterol. Results for the five different Mendelian Randomization methods for two different P-value cut-offs for SNP instrument selection. All methods show a consistent positive effect for an increased risk of ALS with higher total cholesterol levels. There is no evidence for reverse causality. **(b)** Mendelian randomization results for ALS and years of schooling. Error-bars reflex 95% confidence intervals. Statistically significant effects that pass Bonferroni correction for multiple testing for all tested traits and MR methods are marked with an asterisk. Z = genetic instrument, MR = Mendelian Randomization, IVW = inverse-variance weighted, b_{xy} = estimated causal effect for one standard deviation increase in genetically predicted exposure.

Discussion

In summary, in the largest GWAS on ALS to date including 29,612 ALS patients and 122,656 control subjects, we have identified 15 risk loci contributing to ALS risk. Through in-depth analysis of these loci incorporating rare-variant burden analyses and repeat expansion screens in whole-genome sequencing data, blood and brain-specific eQTL and mQTL analysis we have prioritized genes in 14 of the loci. Across the spectrum of neurodegenerative diseases we identified a genetic correlation between ALS and AD, PD and PSP with locus-specific patterns of shared genetic risk across all neurodegenerative diseases. Colocalization analysis identified two additional loci, *GAK* and *BZRAP1-AS1*, with a high posterior probability of shared causal variants between ALS/PD, and ALS/AD respectively. We found glutamatergic neurons as the most enriched cell type in the brain and brain-specific co-expression network enrichment analyses indicated a role for vesicle-mediated transport and autophagy in ALS. Finally, causal inference of previously described risk factors provides evidence for high total cholesterol levels as a causal risk factor for ALS.

The cross-ancestry comparison illustrated similarities in the genetic risk factors for ALS in European and East Asian ancestries, providing an argument for cross-ancestry studies and to further expand ALS GWAS in non-European populations. Important to note is that 3 loci including those that harbor low-frequency variants (*KIF5A*, *SOD1*, and *CFAP410*) were not included in the East Asian GWAS due to their low minor allele frequency. Therefore, the shared genetic risk might not extend to rare genetic variation, for which population-specific frequencies have been observed even within Europe.

The multi-layered gene prioritization analyses highlighted four different classes of genome-wide significant loci in ALS. First, the sample size of this GWAS combined with accurate imputation of low-frequency variants directly identified rare coding variants that increase ALS risk. These include the known p.D90A mutation in *SOD1* (MAF = 0.006) as well as rare variants in *KIF5A* (MAF = 0.016) and *CFAP410* (MAF = 0.012) for which, after their identification through GWAS, experimental work confirms their direct role in ALS pathophysiology.^{9,25,39} Second, we confirmed that the pathogenic *C9orf72* repeat expansion is tagged by genome-wide significant GWAS SNPs, and that no residual signal is left by conditioning the SNP on the repeat expansion. Although more repeat expansions are known to affect ALS risk, we found no similar loci where the SNPs tag a highly pathogenic repeat expansion. This suggests that highly pathogenic repeat expansions on a stable haplotype are merely the exception rather than the rule in ALS. Third, common and rare variant association signals can converge on the same gene as is observed for *NEK1* and *TKB1*, consistent with observations for other traits and diseases^{40–42}. We show that these signals are conditionally independent and that the common variants act on the same gene through regulatory effects as eQTL or mQTL. In the fourth class, we find evidence for regulatory effects of ALS associated SNPs that act as eQTL or mQTL. These locus-specific architectures illustrate the complexity of ALS associated GWAS loci where not one solution fits all, but instead warrants a multi-layered approach to prioritize genes.

In addition, we find locus-specific patterns of shared effects across neurodegenerative diseases. The *MOBP* locus has previously been identified in PSP and ALS and here we show that indeed both diseases, as well as CBD, are likely to share the same causal variant in this locus. The same is true for *UNC13A* and

C9orf72 with FTD and the motor neuron disease subtype of FTD, respectively. The colocalization analysis with PD identified a shared causal variant in the *GAK* locus, which was not found in the ALS GWAS alone. Furthermore the *BZRAP1-AS1* locus harbors SNPs associated with ALS and AD risk. Although this locus was not significant in either of the GWAS, larger GWAS including AD-by-proxy cases confirmed this as a risk locus for AD. This illustrates the power of cross-disorder analyses to leverage the shared genetic risk of neurodegenerative diseases.

We aimed to clarify the role of neuron-specific pathology in ALS susceptibility as opposed to non-cell autonomous pathology through detailed cell-type enrichment analyses. Previous experiments have illustrated multiple lines of evidence for non-cell autonomous pathology in microglia, astrocytes and oligodendrocytes which ultimately leads to neurodegeneration in ALS.^{43–45} These experiments have shown that non-cell autonomous processes, such as neuro-inflammation, mainly act as modifiers of disease in *SOD1* models of ALS^{44,45}. Here, we show that genes within loci associated with ALS susceptibility are specifically expressed in (glutamatergic) neurons. This provides evidence for neuron-specific pathology as a driver of ALS susceptibility, which is in stark contrast to the signal of inflammation associated tissues and cell-types in Alzheimer's disease³⁰. It also shows that disease susceptibility and disease modification can be distinct processes, while both can be targets for potential new treatments in ALS.

The subsequent functional enrichment analyses identified membrane trafficking, Golgi to Endoplasmatic Reticulum (ER) trafficking and autophagy to be enriched for genes within ALS associated loci. These terms and their related Gene Ontology (GO) terms of biological processes are all related to autophagy and degradation of (misfolded) proteins. This corroborates the central hypothesis of impaired protein degradation leading to aberrant protein aggregation in neurons which is the pathological hallmark of ALS. Our results suggest that this is a central mechanism in ALS even in the absence of rare known mutations in genes directly involved in these biological processes such as *TARDBP*, *FUS*, *UBQLN2* and *OPTN*⁴⁶.

Based on observational studies and MR analyses, conflicting evidence exists for lipid levels including cholesterol as a risk factor for ALS^{47–49}. Potential selection bias, reverse causality and the subtype of cholesterol studied challenge the interpretation of these results. Here, we provided support for a causal relationship between high total cholesterol levels and ALS independent of educational attainment and ruling out reverse orientation of the MR effect. The total cholesterol effects were consistent across the different MR methods tested, indicating that this finding is robust to violation of the no horizontal pleiotropy assumption. This is in line with our accompanying study showing methylation changes associated with increased cholesterol levels in ALS³⁵. We do not find a clear pattern for either LDL or HDL cholesterol subtypes in relation to ALS risk. Whereas cholesterol levels are closely related to cardiovascular risk, the association between cardiovascular risk and ALS risk remains controversial with conflicting reports.^{3,47,50} Interestingly, recent work has shown that lipid metabolism and autophagy are closely related which brings results of our pathway analyses and Mendelian randomization together.⁵¹ Both *in vitro* and *in vivo* experiments have shown that autophagy regulates lipid homeostasis through lipolysis and that impaired autophagy increases triglyceride and cholesterol levels. Conversely, high lipid levels were shown to impair autophagy.⁵¹ Further studies on the effect of high cholesterol levels and protein degradation through autophagy illustrate that high cholesterol levels decrease fusogenic ability of autophagic vesicles through decreased SNARE function^{52,53} and lead to increased protein aggregation

due to impaired autophagy in mouse models for Alzheimer's disease⁵⁴. Therefore, the risk increasing effect of cholesterol on ALS might be mediated through impaired autophagy.

In conclusion, our genome-wide association study identifies 15 risk loci in ALS, and illustrates locus-specific interplay between common and rare genetic variation that helps prioritize genes for future follow-up studies. We show a causal role for cholesterol which can be linked to impaired autophagy as common denominators of neuron-specific pathology that drive ALS susceptibility and serve as potential targets for therapeutic strategies.

References

1. van Es, M. A. *et al.* Amyotrophic lateral sclerosis. *Lancet* **390**, 2084–2098 (2017).
2. Al-Chalabi, A., van den Berg, L. H. & Veldink, J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. *Nat Rev Neurol* **13**, 96–104 (2017).
3. Trabjerg, B. B. *et al.* ALS in Danish Registries: Heritability and links to psychiatric and cardiovascular disorders. *Neurology Genetics* **6**, e398 (2020).
4. Ryan, M., Heverin, M., McLaughlin, R. L. & Hardiman, O. Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis. *JAMA Neurol* **76**, 1367–1374 (2019).
5. van Es, M. A. *et al.* Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. *Nat Genet* **41**, 1083–1087 (2009).
6. Laaksovirta, H. *et al.* Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. *Lancet Neurology* **9**, 978–985 (2010).
7. van Rheenen, W. *et al.* Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. *Nat Genet* **48**, 1043–1048 (2016).
8. Benyamin, B. *et al.* Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus with amyotrophic lateral sclerosis. *Nat Commun* **8**, 611 (2017).
9. Nicolas, A. *et al.* Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. *Neuron* **97**, 1268-1283.e6 (2018).
10. Nakamura, R. *et al.* A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. *Commun Biology* **3**, 526 (2020).
11. DeJesus-Hernandez, M. *et al.* Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. *Neuron* **72**, 245–256 (2011).
12. Renton, A. E. *et al.* A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. *Neuron* **72**, 257–268 (2011).
13. Cirulli, E. T. *et al.* Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. *Science* **347**, 1436–1441 (2015).
14. Diekstra, F. P. *et al.* C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genome-wide meta-analysis. *Ann Neurol* **76**, 120–133 (2014).
15. Chen, J. A. *et al.* Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. *Mol Neurodegener* **13**, 41 (2018).
16. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* **48**, 1279–1283 (2016).
17. Kenna, K. P. *et al.* NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. *Nat Genet* **48**, 1037–1042 (2016).
18. Iacoangeli, A. *et al.* Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics. *Cell Reports* **33**, 108323 (2020).
19. Vösa, U. *et al.* Unraveling the polygenic architecture of complex traits using blood eQTL meta-analysis. *bioRxiv* (2018) doi:10.1101/447367.
20. de Klein, N. *et al.* Brain expression quantitative trait locus and network analysis reveals downstream

- effects and putative drivers for brain-related diseases. *bioRxiv* (2021) doi:10.1101/2021.03.01.433439.
21. Pidsley, R. et al. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. *Genome Biol* **17**, 208 (2016).
22. Shireby, G. L. et al. Recalibrating the epigenetic clock: implications for assessing biological age in the human cortex. *Brain* **143**, 3763–3775 (2020).
23. Hannon, E. et al. An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation. *Genome Biol* **17**, 176 (2016).
24. Weeks, E. M. et al. Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases. *medRxiv* (2020) doi:10.1101/2020.09.08.20190561.
25. Fang, X. et al. The NEK1 interactor, C21ORF2, is required for efficient DNA damage repair. *Acta Biochim Biophys Sin* **47**, 834–841 (2015).
26. Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat Genet* **51**, 414–430 (2019).
27. Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. *Lancet Neurol* **18**, 1091–1102 (2019).
28. Ferrari, R. et al. Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurol* **13**, 686–699 (2014).
29. Kouri, N. et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. *Nat Commun* **6**, 7247 (2015).
30. Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. *Nat Genet* **51**, 404–413 (2019).
31. De Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *Plos Comput Biol* **11**, e1004219 (2015).
32. Watanabe, K., Taskesen, E., Bochoven, A. van & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
33. Watanabe, K., Mirkov, M. U., de Leeuw, C. A., van den Heuvel, M. P. & Posthuma, D. Genetic mapping of cell type specificity for complex traits. *Nat Commun* **10**, 3222 (2019).
34. Deelen, P. et al. Improving the diagnostic yield of exome-sequencing by predicting gene–phenotype associations using large-scale gene expression analysis. *Nat Commun* **10**, 2837 (2019).
35. Hop, P. J. et al. Genome-wide study of DNA methylation in Amyotrophic Lateral Sclerosis identifies differentially methylated loci and implicates metabolic, inflammatory and cholesterol pathways. *medRxiv* submitted.
36. Davies, N. M., Holmes, M. V. & Smith, G. D. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* **362**, k601 (2017).
37. Bowden, J. et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. *Int J Epidemiol* **47**, 1264–1278 (2018).
38. Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Smith, G. D. Collider scope: when selection bias can substantially influence observed associations. *Int J Epidemiol* **47**, 226–235 (2017).
39. Watanabe, Y. et al. An Amyotrophic Lateral Sclerosis–Associated Mutant of C21ORF2 Is Stabilized by NEK1-Mediated Hyperphosphorylation and the Inability to Bind FBXO3. *Science* **23**, 101491 (2020).
40. Wood, A. R. et al. Defining the role of common variation in the genomic and biological architecture

of adult human height. *Nat Genet* **46**, 1173–1186 (2014).

41. Luo, Y. et al. Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. *Nat Genet* **49**, 186–192 (2017).

42. Kathiresan, S. et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. *Nat Genet* **40**, 189–197 (2008).

43. Saez-Atienzar, S. et al. Genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types. *Sci Adv* **7**, eabd9036 (2021).

44. Yamanaka, K. et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. *Proc National Acad Sci* **105**, 7594–7599 (2008).

45. Ralph, G. S. et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. *Nat Med* **11**, 429–433 (2005).

46. Blokhuis, A. M., Groen, E. J. N., Koppers, M., van den Berg, L. H. & Pasterkamp, R. J. Protein aggregation in amyotrophic lateral sclerosis. *Acta Neuropathol* **125**, 777–794 (2013).

47. Seelen, M. et al. Prior medical conditions and the risk of amyotrophic lateral sclerosis. *J Neurol* **261**, 1949–1956 (2014).

48. Bandres-Ciga, S. et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. *Ann Neurol* **85**, 470–481 (2019).

49. Armon, C. Smoking is a cause of ALS. High LDL-cholesterol levels? Unsure. *Ann Neurol* (2019) doi:10.1002/ana.25469.

50. Turner, M. R., Wotton, C., Talbot, K. & Goldacre, M. J. Cardiovascular fitness as a risk factor for amyotrophic lateral sclerosis: indirect evidence from record linkage study. *J Neurology Neurosurg Psychiatry* **83**, 395 (2012).

51. Singh, R. et al. Autophagy regulates lipid metabolism. *Nature* **458**, 1131–1135 (2009).

52. Koga, H., Kaushik, S. & Cuervo, A. M. Altered lipid content inhibits autophagic vesicular fusion. *Faseb J* **24**, 3052–3065 (2010).

53. Fraldi, A. et al. Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders. *Embo J* **29**, 3607–3620 (2010).

54. Barbero-Camps, E. et al. Cholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion. *Autophagy* **14**, 1–26 (2018).

Methods

GWAS

Data description

We obtained individual genotype level data for all individuals in the previously published GWAS in ALS in European ancestries^{7,9} and publicly available control datasets including 120,971 controls genotyped on Illumina platforms. Additionally 6,374 cases and 22,526 controls were genotyped on the IlluminaOmniExpress and Illumina GSA array. Details for each cohort are provided in **Supplementary Table 1**. For ALS cases, both cases with and without a family-history for ALS and/or dementia were included. Cases were not pre-screened for specific ALS related mutations. Given the late onset and relatively low life-time risk of ALS, controls were not screened for (subclinical) signs of ALS. A detailed description of the newly genotyped cases and controls is provided in the **Supplementary Information**. All participants gave written informed consent and the relevant local institutional review boards approved this study (**Supplementary Information**). Cases and controls formed cohorts when they were processed in the same lab and were genotyped in the same batch, resulting in 117 independent cohorts.

GWAS quality control and imputation

For each cohort, SNPs were first annotated according to dbSNP150 and mapped to the hg19 reference genome. All multi-allelic and palindromic (A/T or C/G) SNPs were excluded. Subsequently, basic quality control was first performed by cohort, excluding extremely low-quality SNPs and genotyped individuals as well as excluding extreme population outliers. Low quality SNPs and genotyped individuals were excluded using PLINK 1.9 (--geno 0.1 and --mind 0.1)⁵⁵. Population structure was assessed by projecting HapMap3 principal components (PCs) using EIGENSOFT⁵⁶ 6.1.4. Extreme outliers from the European ancestries population were removed (> 25 SD on PC1-4). Finally, cohorts were merged into strata based on genotyping platforms to preserve the maximum number of SNPs (**Supplementary Table 2**). Four out of 6 strata were formed by only a single platform. The remaining two strata included multiple platforms with 420,952 and 299,625 overlapping SNPs across platforms in these strata.

After excluding major SNP and sample outliers in cohort QC and merging cohorts into strata, stringent SNP QC was performed per stratum. The following filter criteria were applied: MAF > 0.01, SNP genotyping rate > 0.98, Deviation from Hardy-Weinberg disequilibrium in controls $P > 1 \times 10^{-5}$, and haplotype-biased missingness $P > 1 \times 10^{-8}$ (PLINK --maf 0.01, --geno 0.02, --hwe 1e-5 midp include-nonctrl, --test-mishap). Then, more stringent QC thresholds were applied to exclude individuals: individual missingness > 0.02, inbreeding coefficient $|F| > 0.2$, mismatches between genetic and reported gender, and missing phenotypes (PLINK --mind 0.02, --het, --check-sex). Subsequently, SNPs with a differential missingness (--test-missing midp) $P < 1 \times 10^{-4}$ were excluded. Duplicate individuals were removed (PI_HAT > 0.8). Finally, outliers from the European ancestries reference population (projected on HapMap 3: > 10 SD from CEU

on PC1-4 and projected on 1000 Genomes: > 4 SD from CEU on PC1-4) and outliers within the stratum itself (> 4SD from stratum mean on PC1-4) were removed (**Supplementary Figures 54-59**).

After removing outliers, principal components were recalculated for each stratum. To assess the result of quality control prior to imputation, genomic inflation factors per stratum were calculated using SAIGE⁵⁷ to run a logistic mixed model regressing SNP genotype on ALS case-control status. SAIGE internally calculates an equivalent of a genetic relationship matrix to correct for relatedness and population structure. Additionally, PC1-20 and genotyping platform were included as covariates.

The number of individuals and SNPs passing quality control for each stratum prior to imputation is described in **Supplementary Table 2**.

Post Imputation quality control

Strata were then imputed using the HRC reference panel (r.1.1 2016) on the Michigan Imputation Server¹⁶. Data was phased using Eagle 2.3. After imputation, one individual of each pair of related samples across strata (PI_HAT > 0.125) was removed whereas related pairs within a stratum were retained since the genetic relationship matrix corrects for relatedness. Post-imputation variant-level quality control included removing all monomorphic SNPs and multi-allelic SNPs from each stratum. SNPs with MAF < 0.1% in the HRC imputation panel were excluded. Subsequently, INFO scores were calculated for each stratum based on dosage information using SNPTEST⁵⁸ v2.5.4-beta3. Within each stratum, SNPs with an INFO-score < 0.6 and those deviating from Hardy-Weinberg equilibrium at $P < 1 \times 10^{-5}$ in control subjects were removed. Effective sample size was calculated for each stratum:

$$N_{effective} = \frac{4 \cdot N_{cases} \cdot N_{controls}}{N_{cases} + N_{controls}}$$

The difference in sample size and number of SNPs for each stratum prior to imputation, resulted in a different set of SNPs passing post-imputation quality control for each stratum. Therefore, only SNPs that were successfully imputed in an effective sample meeting > 50% of the maximum effective sample size were included.

The number of individuals and SNPs passing quality control for each stratum after imputation is described in **Supplementary Table 2**.

Association testing and meta-analysis

After quality control, a null logistic mixed model was fitted using SAIGE⁵⁷ 0.29.1 for each stratum with PC1-20 as covariates. The model was fit on a set of high-quality (INFO > 0.95), pruned with PLINK 1.9, (--indep-pairwise 50 25 0.1) SNPs in a leave-one-chromosome-out scheme. Subsequently, a SNP-wise logistic mixed model including the saddle point approximation test was performed using genotype dosages with SAIGE. Association statistics for all strata were combined in an inverse variance-weighted fixed effects meta-analysis using METAL⁵⁹.

Genomic inflation factors were calculated per stratum and for the full meta-analysis. To assess any residual confounding due to population stratification and artificial structure in the data we calculated the LD Score regression (LDSC)⁶⁰ intercept using SNP LD-scores calculated in the HapMap3 CEU population.

Cross-ancestry analyses.

GWAS summary statistics from two Asian ancestry studies were obtained^{8,10}. These summary statistics were meta-analyzed with all European ancestry in strata as described above. To assess genetic correlation for ALS in the European and Asian ancestries, we used Popcorn⁶¹ version 0.9.9. We used population specific LD scores for genetic impact and genetic effect provided with the Popcorn software. The regression model (--use_regression) was used to estimate genetic correlation. We calculated both the correlation of genetic effects (correlation of allelic effect sizes) and genetic impact (correlation of allelic effect size adjusted for difference in allele frequencies).

Conditional SNP analysis

Conditional and joint SNP analysis (COJO, GCTA v1.91.1b)^{62,63} was performed to identify potential secondary GWAS signals within a single locus. SNPs with association $P \leq 5 \times 10^{-8}$ were considered. European ancestry controls from the health and retirement study (HRS, cohort 65, **Supplementary Table 1**), included in stratum 4 of this study, were used as LD reference panel.

Gene prioritization.

Whole-genome sequencing

Sample selection, sequencing and data preparation.

ALS cases and controls from Project MinE⁶⁴ were recruited for whole genome sequencing. The participating cohorts are described in the **Supplementary Note**. A full description of Project MinE, the sequencing and quality control pipeline were described previously⁶⁵. In summary, the first batch of 2,250 cases and control samples were sequenced on the Illumina HiSeq 2000 platform. All remaining 7,350 cases and controls were sequenced on the Illumina HiSeq X platform. All samples were sequenced to ~35X coverage with 100bp reads and ~25X coverage with 150bp reads for the HiSeq 2000 and HiSeq X respectively. Both sequencing sets used PCR-free library preparation. Samples were also genotyped on the Illumina 2.5M array. Sequencing data was then aligned to GRCh37 using the iSAAC Aligner, and variants called using the iSAAC variant caller; both the aligner and caller are standard to Illumina's aligning and calling pipeline.

Quality control

For variant-level quality control, we set sites with a genotype quality (GQ) < 10 to missing and SNVs and indels with quality (QUAL) scores < 20 and < 30, respectively, were removed. We subsequently performed

sample-level quality control. An overview of the number of samples that have been excluded at each of the following QC steps, stratified by country of origin, is included in **Supplementary Table 3**.

We estimated kinship coefficients (i.e., relatedness) using the KING method, as implemented in the SNPRelate package in R. In some instances, cohorts were intentionally enriched for related samples. We identified all pairs of related individuals (kinship > 0.0625).

We calculated the transition-transversion ratio in each sample using SnpSift 4.3p. In WGS data, the expected transition-transversion ratio is ~2.0. Samples with a Ti/Tv ratio $\pm$ 6 SD from the full distribution of samples were removed.

Per sample, we calculated the total number of SNVs and total number of singletons. We removed samples with a total number of SNVs or Singletons > 6 SD from the mean. The transition in sequencing platforms from HiSeq 2000 to HiSeq X (which occurred in parallel with a change in the calling pipeline, to improve indel detection) caused an increase in observed indels per sample. Samples were thus filtered by platform (HiSeq 2000 or HiSeq X) and removed samples with number of indels $\pm$ 6 SD from the mean of their respective group.

We calculated average sample depth and again observed noticeable differences between those samples sequenced on the HiSeq 2000 and the HiSeq X, where average depth of coverage was somewhat higher (35X, on average) for samples sequenced on HiSeq 2000 compared to the samples sequenced on the HiSeqX (25X, on average). We removed no samples at this step.

Using the genetically inferred sex based on the number of X and Y chromosome, we tested to see if the inferred genetic sex was concordant with the sex as annotated in the available phenotype information. We excluded samples with mismatching information and samples for which phenotypic information is missing at this time.

We performed the remaining sample QC on high-quality variants: We removed all multi-allelic SNVs, PLINK 1.9 (--geno), variants with a missingness > 2% were excluded. We calculated Hardy-Weinberg equilibrium (HWE) in controls only, PLINK 1.9 (--hwe midp), and removed all variants with HWE $P < 1 \times 10^{-5}$. We calculated differential missingness, PLINK 1.9 (--test-mishap) between cases and controls and removed variants with $P < 1 \times 10^{-8}$. Samples with a missingness > 2%, in SNV and indels, were excluded. Final steps of sample QC was performed on a set of variants with a MAF > 10%, SNP missingness < 0.1%, variants residing outside four complex regions (the major histocompatibility complex (MHC) on chromosome 6; the lactase locus (LCT), on chromosome 2; and inversions on chromosomes 8 and 17); and we excluded the A/T and C/G variants. We used the SNVs to calculate observed and expected autosomal homozygous genotype counts for each sample PLINK 1.9 (--het); samples with $|F| > 0.1$ were excluded. We excluded duplicate samples; PLINK 1.9 (--genome) with a PIHAT > 0.8, keeping the maximum number of non-duplicated individuals.

Principal component analysis (PCA) implemented in EIGENSOFT was used to visualize potential structure in the data, induced by population stratification or other variables. Projections onto HapMap3 and the 1KG phase3 v5 populations indicated that the samples were primarily of European ancestry, though some

were of African or East Asian ancestries, while other samples appeared to be admixed. Outliers from the European population (HapMap3: > 10 SD on PC1-4, 1KG: > 4 SD on PC1-4).

All samples were sent in batches to Illumina for sequencing. To prevent spurious association due to batch specific artifacts, we regressed all variants on a dummy coded variable indicating batch using PLINK 1.9 (-logistic). All variants with an association $P < 1 \times 10^{-10}$ in at least 1 batch were excluded.

Genic burden association analyses

To aggregate rare variants in a genic burden test framework we used a variety of variant filters to allow for different genetic architectures of ALS associated variants per gene as we and others have used previously^{65,66}. In summary, variants were annotated according to allele-frequency threshold (MAF < 0.01 or MAF < 0.005) and predicted variant impact (“missense”, “damaging”, “disruptive”). “Disruptive” variants were those variants classified as frame-shift, splice-site, exon loss, stop gained, start loss and transcription ablation. “Damaging” variants were missense variants predicted to be damaging by seven prediction algorithms (SIFT⁶⁷, Polyphen-2⁶⁸, LRT⁶⁹, MutationTaster2⁷⁰, Mutations Assessor⁷¹, and PROVEAN⁷²). “Missense” variants are those missense variants that did not meet the “damaging” criteria. All combinations of allele frequency threshold and variant annotations were used to test the genic burden on a transcript level in a Firth logistic regression framework where burden was defined as the number of variants per individual. Sex and the first 20 principal components were included as covariates. All ENSEMBL protein coding transcripts for which at least five individuals had a non-zero burden were included in the analysis.

Conditional genic burden analysis.

We selected for each gene the protein coding transcripts that were strongest associated with ALS across all different combinations of MAF and variant impact thresholds that exhibited the strongest association with ALS. For these transcripts and variants, we applied Firth logistic regression on individuals overlapping the GWAS and WGS dataset (5,158 cases and 2,167 controls). To assess whether the rare variant burden association and the signal from GWAS were conditionally independent we subsequently included the genotype of the top-associated SNP within that locus as covariate.

Short tandem repeat screen

For all individuals that were sequenced on the HiSeqX dataset (5,392 cases, 1,795 controls) we screened all loci harboring SNPs associated with ALS meeting genome-wide significance for expansions of known and new short tandem repeats (STRs) using ExpansionHunter⁷³ and ExpansionHunter Denovo⁷⁴.

First we used ExpansionHunter (v4.0) to screen for expansions of known STRs located within 1 MB of the top ALS-associated SNP. For this we used the STR catalogue of the ExpansionHunter software which is based on STRs identified from indels in 18 high quality genomes and the gangSTR STR catalogue based on STR annotations in the reference genome⁷⁵. From these catalogues, we excluded all homopolymers. Repeat length was subsequently regressed on case-control status using Firth logistic regression including the first 20 principal components as covariates, recoding the STR size to a biallelic variant using a sliding

window over all observed repeat lengths. To correct for multiple testing across all possible thresholds, we applied Benjamini Hochberg correction per STR.

To screen for extremely long STR expansions (similar to the *C9orf72* repeat expansion) at loci that not included in the predefined STR catalogues, we applied ExpansionHunter-Denovo⁷⁴. This method aims to only find STR expansions that exceed the sequencing read-length (> 150 bp) by identifying reads (mapped, mismapped and unmapped) that contain STR motifs, using their mate pairs for *de novo* mapping to the reference genome.

For all STRs we calculated linkage disequilibrium statistics (r^2 and $|D'|$) between recoded repeat genotypes at the optimal threshold and the top associated GWAS SNP. Subsequently, we conditioned the SNP association on the repeat genotype in a Firth logistic regression.

Summary-based Mendelian randomization

We used multi-SNP SMR^{76,77} to infer the effect of gene expression variation on ALS using eQTLs (the association of a SNP with expression of a gene) on ALS risk. MetaBrain is a harmonized set of 8,727 RNA-seq samples from 7 regions of the central nervous system from 15 datasets, and we selected eQTLs derived from the cortex region of the brain in samples of European ancestry (MetaBrain Cortex-EUR eQTLs) as our instrument variable²⁰. The European-only ALS summary statistics were used as the outcome. To supplement this analysis, we also used eQTLs in blood from the eQTLGen consortium, as this is the largest eQTL resource available. European-ancestry samples in the Health and Retirement study (HRS, cohort 65 of this GWAS) were used as LD reference panel. SNP with MAF $\geq 1\%$ in HRS were included. Further SMR settings were left as default, meaning probes with at least one eQTL with $P \leq 5 \times 10^{-8}$ were included.

We subsequently performed SMR using DNA methylation QTL (mQTL) data and European-only ALS summary statistics. Human prefrontal cortex and whole blood DNA mQTLs were generated as part of ongoing analyses by the Complex Disease Epigenomics Group at the University of Exeter (www.epigenomicslab.com) using the Illumina EPIC HumanMethylation array that quantifies DNAm at >850,000 sites across the genome²¹. The prefrontal cortex mQTL dataset was generated using DNA methylation and SNP data from 522 individuals from the Brains for Dementia Research cohort²² and included 4,623,966 cis mQTLs (distance between QTL SNP and DNAm site ≤ 500 kb) between 1,744,102 SNPs and 43,337 DNA methylation sites. The whole blood mQTL dataset was generated using DNAm and SNP data from 2,082 individuals⁷⁸ and included 30,432,023 cis mQTLs between 4,030,902 SNPs and 167,854 DNA methylation sites. mQTLs reaching the significance threshold $P \leq 1 \times 10^{-10}$ were taken forward for SMR analysis as described by Hannon and colleagues⁷⁸. To map CpG sites to their putative target genes we used the expression quantitative trait methylation (eQTM) results from a paired methylation and gene expression (RNA-seq) study in blood⁷⁹. For CpG sites where no eQTM were present in this dataset, we used positional mapping based on the basal regulatory domains and extended regulatory domains as defined in the Genomic Regions Enrichment of Annotations Tool (GREAT)⁸⁰ which is applied in the ``cpg_to_gene`` function in the CpGtools toolkit⁸¹.

Polygenic Priority Score (PoPS)

We used the polygenic priority score (PoPS²⁴ v0.1) to rank genes according to the gene features that were enriched in ALS. For this we applied MAGMA in the European ancestries GWAS since it depends on an LD reference panel (1000 Genomes Project, EUR population) to obtain gene-wise association statistics. We used the default 57,543 gene features that were based on expression data, protein-protein interaction networks and pathway membership. Genes were ranked based on the Polygenic Priority Score.

Cross-trait analyses in neurodegenerative diseases.

Datasets and data preparation

GWAS summary statistics for clinically-diagnosed Alzheimer's disease (AD)²⁶, Parkinson's disease (PD)²⁷, frontotemporal dementia (FTD)²⁸, corticobasal degeneration (CBD)²⁹, and progressive supranuclear palsy (PSP)¹⁵ in European ancestry individuals were obtained. For Alzheimer's disease we used the clinically diagnosis as case definition to avoid spurious genetic correlations that could have been introduced through the by-proxy design³⁰ where by-proxy cases are defined as having a parent with Alzheimer's disease. Although this is a powerful design for gene discovery and the genetic correlation with clinically diagnosed Alzheimer's disease is high⁸², mislabeling by-proxy cases when parents suffer from other types of dementia (e.g. Lewy-body dementia, Parkinson's dementia, FTD, or vascular dementia) can lead to spurious genetic correlations with ALS and other neurodegenerative diseases. For FTD, we primarily used the results of the cross-subtype meta-analysis which includes behavioral variant FTD (bvFTD), semantic dementia (sdFTD), progressive non-fluent aphasia (pnfaFTD) and motor neuron disease FTD (mndFTD). For CBD, allele coding were missing and effect alleles were inferred by matching allele frequencies to those observed in the Haplotype Reference Consortium. SNPs with minor allele frequency > 0.4 were excluded. Since downstream methods rely on LD-scores or population-specific LD patterns, the European ancestry summary statistics from the present study were used for ALS. For sample size parameters, effective sample size was calculated as described previously.

Genetic correlation

We first assessed residual confounding through estimating the LD Score regression⁶⁰ intercept using LDSC (v.1.0.0): ALS = 1.03 (SE 0.0073), AD = 1.03 (SE 0.013), PD = 0.98 (SE 0.0065), PSP = 1.05 (SE 0.0076), CBD = 0.98 (SE 0.0073), FTD = 1.00 (SE 0.0071), showing limited inflation of test statistics due to confounding across these studies. Genome-wide genetic correlation between neurodegenerative traits was calculated using LDSC (v1.0.0). Pre-computed LD-scores of European individuals in the 1000 Genomes project for high-quality HapMap3 SNPs were used (eur_w_ld_chr). A free intercept was modelled to allow for potential sample overlap.

Colocalization

For each locus (top-SNP +/- 100KB) harboring SNPs with an association with any of the neurodegenerative diseases at $P < 1 \times 10^{-5}$ we performed colocalization analysis using the `coloc` package in R.⁸³ We set the

prior probabilities to $\pi_1 = 1 \times 10^{-4}$, $\pi_2 = 1 \times 10^{-4}$, $\pi_{12} = 1 \times 10^{-5}$ for a causal variant in trait 1, trait 2 and a shared causal variant between trait 1 and 2 respectively. Using the same parameters, we performed colocalization analysis for ALS and each of the FTD subtypes (bvFTD, sdFTD, pnfaFTD, mndFTD).

Enrichment analyses

LD-score regression annotation-specific enrichment analysis

We used LDSC (v1.0.0) to calculate SNP-based heritability, the LDSC intercept and SNP-based heritability enrichment for partitions of the genome. In all LDSC analyses, summary statistics excluding the HLA region of only European ancestry samples were included. LD scores and partitioned LD scores provided by LDSC were used for genome-wide and genic region-based heritability analyses. The option --overlap-annot was used in the partitioned heritability analysis to allow for overlapping SNP between MAF bins. SNPs with a MAF > 5% were included.

Tissue and cell-type enrichment analysis

Tissue and cell-type enrichment analyses were performed using the GWAS summary statistics of the European ancestries meta-analysis and FUMA³² software v1.3.6a. FUMA performs a genic aggregation analysis of GWAS association signals to calculate gene-wise association signals using MAGMA v1.6 and subsequent tests whether tissues and cell-types are enriched for expression of these genes. For tissue enrichment analysis we used the GTEx v8 reference set. For cell-type enrichment analyses³³ we used human-derived single-cell RNA sequencing data on major brain cell-types (GSE67835 without fetal samples⁸⁴), the Allen Brain Atlas Cell-type⁸⁵ for the human-derived major neuronal subtypes and the DropViz⁸⁶ dataset for mouse-derived brain cell-types across all brain regions.

Pathway enrichment analysis

We used the Downstreamer software²⁰ to identify enriched biological pathways and processes. First, gene-based association statistics are obtained through the PASCAL method⁸⁷ which aggregates SNP association statistics including SNPs up to 10kb up- and downstream of a gene, accounting for linkage disequilibrium using the non-Finish European individuals from the 1000 Genomes Project phase 3 (ref. ⁸⁸) as a reference. In the Downstreamer method, putative core genes are defined as those that are coexpressed with disease-associated genes and can therefore be implicated in disease. Co-expression networks are based on either a large, multi-tissue transcriptome dataset including 56,435 genes and 31,499 individuals, or brain-specific RNA-sequencing data obtained in the MetaBrain resource. The gene-based association statistics, co-expression matrix and gene Z-scores per pathway or HPO term are then combined in a generalized least squares regression model to obtain enrichment statistics.²⁰ Enrichment analyses were performed for Reactome, Gene Ontology and Human Phenotype Ontology (HPO) terms using the multi-tissue or brain-specific transcriptome datasets to calculate the co-expression matrix.

The distribution of enrichment Z-score statistics were compared between the analyses using the multi-tissue or the brain-specific co-expression matrices. Using the 'pyhpo' module in Python, all HPO terms

were assigned to their parent term(s) in the “*Phenotypic abnormality*” (HP:0000118) branch which includes phenotypic abnormalities grouped per organ system.

Mendelian Randomization

Causal inference through MR analysis was performed for 22 exposures for which large-scale GWAS are available and for which there is prior evidence for an association with ALS. These include 7 behavioral related traits: body mass index (anthropometric)⁸⁹, years of schooling (educational attainment)⁹⁰, alcoholic drinks per week, age of smoking initiation and cigarettes per day from Liu et al.⁹¹, days per week moderate physical activity and days per week vigorous activity from UK Biobank⁹²; 4 blood pressure traits: coronary artery disease⁹³, stroke⁹⁴, diastolic blood pressure and systolic blood pressure⁹⁵; 7 immune system traits from Vuckovic et al.⁹⁶ (basophil, eosinophil, lymphocyte, monocyte, neutrophil and white blood cells) and C-reactive protein⁹⁷; and 4 lipid traits from Willer et al.⁹⁸ (HDL cholesterol, LDL cholesterol, total cholesterol and triglycerides). A full description of the included studies is provided in **Supplementary Table 25**. From these GWASs, SNPs to serve as instruments for MR analyses were selected at two different p-value cut-offs ($P < 5 \times 10^{-8}$ and $P < 5 \times 10^{-5}$) and then LD clumped to obtain independent SNPs. SNP effect estimates on ALS risk were obtained from the European ancestries only GWAS and if needed an LD-proxy was selected ($r^2 > 0.8$).

After harmonizing effect-alleles and excluding palindromic SNPs, we performed a series of quality control steps to avoid biased estimates of causal effects, checking for each exposure the (i) instrument coverage (> 85% overlapping SNPs, **Supplementary Table 30**), (ii) instrument strength (F-statistic^{36,99,100} > 10, **Supplementary Table 31**), (iii) distribution and significance of the Wald ratios (visual inspection of volcano plots, **Supplementary Table 32**) and (iv) heterogeneity across the instrument-exposure effects (Q-statistic at $P < 0.05$ indicating heterogeneity, **Supplementary Table 33**).

We applied 5 different MR methods: Inverse variance weighted (IVW) using the random effects model, MR-Egger, simple mode, weighted median and weighted mode methods. When only a single SNP was available the Wald ratio (WR) test was conducted. MR analysis was conducted in R using the ``mr()`` function in the ``TwoSampleMR`` package¹⁰¹.

Subsequently, Radial MR analysis was conducted to determine if Wald ratio outliers needed to be removed from the IVW or MR-Egger MR estimates³⁷. In addition, we conducted a Q-test to identify outlier SNPs ($P < 0.05$). These outliers were then removed from the original MR analyses (across all 5 MR methods). The Radial MR analysis was conducted using the RadialMR R package (<https://github.com/WSpiller/RadialMR>). In order to determine that the MR effects were orientated in the correct direction (from exposure to ALS) we conducted both reverse MR¹⁰² and Steiger filtering¹⁰³ on our top MR findings.

Finally, we explored whether the MR effects of our total and LDL cholesterol and systolic blood pressure exposures may be confounded by the effect we observed for years of schooling by conducting multivariate MR analysis¹⁰⁴. Conditional F and Q statistics were calculated using the ``MVMR`` package¹⁰⁵ in R.

Data availability

All summary statistics will be made publicly available in centralized repositories upon publication.

References for methods

55. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 1–16 (2015).
56. Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* **38**, 904–909 (2006).
57. Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nat Genet* **50**, 1335–1341 (2018).
58. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat Genet* **39**, 906–913 (2007).
59. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
60. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).
61. Brown, B. C., Asian Genetic Epidemiology Network Type-2 Diabetes Consortium, Ye, C. J., Price, A. L. & Zaitlen, N. Transethnic Genetic-Correlation Estimates from Summary Statistics. *Am J Hum Genetics* **99**, 76–88 (2016).
62. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet* **44**, 369–375 (2012).
63. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: A Tool for Genome-wide Complex Trait Analysis. *Am J Hum Genetics* **88**, 76–82 (2011).
64. Project MinE Consortium. Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. *Eur J Hum Genet* **26**, 1537–1546 (2018).
65. van der Spek, R. A. A. et al. The project MinE databrowser: bringing large-scale whole-genome sequencing in ALS to researchers and the public. *Amyotroph Lateral Scler Frontotemporal Degener* **20**, 432–440 (2019).
66. Genovese, G. et al. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. *Nat Neurosci* **19**, 1433–1441 (2016).
67. Vaser, R., Adusumalli, S., Leng, S. N., Sikic, M. & Ng, P. C. SIFT missense predictions for genomes. *Nat Protoc* **11**, 1–9 (2016).
68. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. *Nat Methods* **7**, 248–249 (2010).
69. Chun, S. & Fay, J. C. Identification of deleterious mutations within three human genomes. *Genome Res* **19**, 1553–1561 (2009).
70. Schwarz, J. M., Cooper, D. N., Schuelke, M. & Seelow, D. MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods* **11**, 361–362 (2014).
71. Reva, B., Antipin, Y. & Sander, C. Predicting the functional impact of protein mutations: application

- to cancer genomics. *Nucleic Acids Res* **39**, e118–e118 (2011).
72. Choi, Y. & Chan, A. P. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. *Bioinformatics* **31**, 2745–2747 (2015).
73. Dolzhenko, E. et al. Detection of long repeat expansions from PCR-free whole-genome sequence data. *Genome Res* **27**, 1895–1903 (2017).
74. Dolzhenko, E. et al. ExpansionHunter Denovo: a computational method for locating known and novel repeat expansions in short-read sequencing data. *Genome Biol* **21**, 102 (2020).
75. Mousavi, N., Shleizer-Burko, S., Yanicky, R. & Gymrek, M. Profiling the genome-wide landscape of tandem repeat expansions. *Nucleic Acids Res* **47**, e90–e90 (2019).
76. Wu, Y. et al. Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. *Nat Commun* **9**, 918 (2018).
77. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat Genet* **48**, 481–487 (2016).
78. Hannon, E. et al. Leveraging DNA-Methylation Quantitative-Trait Loci to Characterize the Relationship between Methylomic Variation, Gene Expression, and Complex Traits. *Am J Hum Genetics* **103**, 654–665 (2018).
79. Hop, P. J. et al. Genome-wide identification of genes regulating DNA methylation using genetic anchors for causal inference. *Genome Biol* **21**, 220 (2020).
80. McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions. *Nat Biotechnol* **28**, 495–501 (2010).
81. Wei, T. et al. CpGtools: A Python Package for DNA Methylation Analysis. *Bioinformatics*, 1-2 (2019) doi:10.1093/bioinformatics/btz916.
82. Marioni, R. E. et al. GWAS on family history of Alzheimer’s disease. *Transl Psychiatry* **8**, 99 (2018). doi:10.1038/s41398-018-0150-6
83. Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. *Plos Genet* **10**, e1004383 (2014).
84. Darmanis, S. et al. A survey of human brain transcriptome diversity at the single cell level. *Proc National Acad Sci* **112**, 7285–7290 (2015).
85. Hodge, R. D. et al. Conserved cell types with divergent features in human versus mouse cortex. *Nature* **573**, 61–68 (2019).
86. Saunders, A. et al. Molecular Diversity and Specializations among the Cells of the Adult Mouse Brain. *Cell* **174**, 1015-1030.e16 (2018).
87. Lamparter, D., Marbach, D., Rueedi, R., Kutalik, Z. & Bergmann, S. Fast and Rigorous Computation of Gene and Pathway Scores from SNP-Based Summary Statistics. *Plos Comput Biol* **12**, e1004714 (2016).
88. Auton, A. et al. A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
89. Yengo, L. et al. Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. *Hum Mol Genet* **27**, 3641–3649 (2018).
90. Lee, J. J. et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet* **50**, 1112–1121 (2018).
91. Liu, M. et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet* **51**, 237–244 (2019).
92. Sudlow, C. et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of

- Complex Diseases of Middle and Old Age. *Plos Med* **12**, e1001779 (2015).
93. van der Harst, P. & Verweij, N. Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease. *Circ Res* **122**, 433–443 (2018).
 94. Malik, R. et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* **50**, 524–537 (2018).
 95. Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat Genet* **50**, 1412–1425 (2018).
 96. Vuckovic, D. et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. *Cell* **182**, 1214–1231.e11 (2020).
 97. Ligthart, S. et al. Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. *Am J Hum Genetics* **103**, 691–706 (2018).
 98. Willer, C. J. et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet* **45**, 1274–1283 (2013).
 99. Zeng, P., Wang, T., Zheng, J. & Zhou, X. Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics. *BMC Med* **17**, 225 (2019).
 100. Cragg, J. G. & Donald, S. G. Testing Identifiability and Specification in Instrumental Variable Models. *Economet Theor* **9**, 222–240 (1993).
 101. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife* **7**, e34408 (2018).
 102. Smith, G. D. & Hemani, G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* **23**, R89–R98 (2014).
 103. Hemani, G., Tilling, K. & Smith, G. D. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLOS Genet* **13**, e1007081 (2017).
 104. Burgess, S. & Thompson, S. G. Multivariable Mendelian Randomization: The Use of Pleiotropic Genetic Variants to Estimate Causal Effects. *Am J Epidemiol* **181**, 251–260 (2015).
 105. Sanderson, E., Smith, G. D., Windmeijer, F. & Bowden, J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *Int J Epidemiol* **48**, 713–727 (2018).

Consortium members

SLALOM Consortium

Ettore Beghi⁴², Elisabetta Pupillo⁴², Giancarlo Comi¹⁴⁰, Nilo Riva¹⁴⁰, Christian Lunetta¹⁴¹, Francesca Gerardi¹⁴¹, Maria Sofia Cotelli¹⁴², Fabrizio Rinaldi¹⁴², Luca Chiveri¹⁴³, Maria Cristina Guaita¹⁴⁴, Patrizia Perrone¹⁴⁴, Mauro Ceroni¹⁴⁵, Luca Diamanti¹⁴⁵, Carlo Ferrarese¹⁴⁶, Lucio Tremolizzo¹⁴⁶, Maria Luisa Delodovici¹⁴⁷ & Giorgio Bono¹⁴⁷

Affiliations

42: Laboratory of Neurological Diseases, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

140: IRCCS San Raffaele Hospital, Milan, Italy.

141: NEMO Clinical Center, Serena Onlus Foundation, Niguarda Ca' Granda Hospital, Milan, Italy.

142: Civil Hospital of Brescia, Brescia, Italy.

143: Ospedale Valduce, Como, Italy.

144: A.O. Ospedale Civile di Legnano, Legnano, Italy.

145: IRCCS Istituto Neurologico Nazionale "C.Mondino", Pavia, Italy.

146: A.O. "San Gerardo" di Monza and University of Milano-Bicocca, Italy

147: A.O. "Ospedale di Circolo Fondazione Macchi" di Varese, Varese, Italy.

PARALS Consortium

Adriano Chiò^{40,41}, Andrea Calvo^{40,41}, Cristina Moglia^{40,41}, Antonio Canosa^{40,41,148}, Umberto Manera⁴⁰, Rosario Vasta⁴⁰, Alessandro Bombaci⁴⁰, Maurizio Grassano⁴⁰, Maura Brunetti⁴⁰, Federico Casale⁴⁰, Giuseppe Fuda⁴⁰, Paolina Salamone⁴⁰, Barbara Iazzolino⁴⁰, Laura Peotta⁴⁰, Paolo Cugnasco⁴⁰, Giovanni De Marco⁴¹, Maria Claudia Torrieri⁴⁰, Francesca Palumbo⁴⁰, Salvatore Gallone⁴¹, Marco Barberis¹⁴⁹, Luca Sbaiz¹⁴⁹, Salvatore Gentile¹⁵⁰, Alessandro Mauro^{40,151}, Letizia Mazzini^{152,153}, Fabiola De Marchi^{152,153}, Lucia Corrado^{154,153}, Sandra D'Alfonso^{154,153}, Antonio Bertolotto¹⁵⁵, Maurizio Gionco¹⁵⁶, Daniela Leotta¹⁵⁷, Enrico Odddenino¹⁵⁷, Daniele Imperiale¹⁵⁸, Roberto Cavallo¹⁵⁹, Pietro Pignatta¹⁶⁰, Marco De Mattei¹⁶¹, Claudio Geda¹⁶², Diego Maria Papurello¹⁶³, Graziano Gusmaroli¹⁶⁴, Cristoforo Comi^{165,166}, Carmelo Labate¹⁶⁷, Luigi Ruiz¹⁶⁸, Delfina Ferrandi¹⁶⁹, Eugenia Rota¹⁷⁰, Marco Aguggia¹⁷¹, Nicoletta Di Vito¹⁷¹, Piero Meineri¹⁷², Paolo Ghiglione¹⁷³, Nicola Launaro¹⁷⁴, Michele Dotta¹⁷⁵, Alessia Di Sapio¹⁷⁶ & Guido Giardini¹⁷⁷

Affiliations

40: "Rita Levi Montalcini" Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.

41: Neurologia 1, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Turin, Italy.

148: Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Neurology Unit 1U, Turin, Italy.

149: Department of Medical Genetics, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Turin, Italy.

150: Neurologia 3, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.

151: Istituto Auxologico Italiano, IRCCS, Piacavallo, Italy.

152: Department of Neurology, 'Amedeo Avogadro' University of Piemonte Orientale, Novara, Italy.

153: Azienda Ospedaliero Universitaria 'Maggiore della Carità', Novara, Italy.

154: Department of Health Sciences, 'Amedeo Avogadro' University of Piemonte Orientale, Novara, Italy.

155: Department of Neurology and Multiple Sclerosis Center, Azienda Ospedaliero Universitaria San Luigi, Orbassano, Italy.

156: Department of Neurology, Azienda Ospedaliera 'Ordine Mauriziano' di Torino, Turin, Italy.

157: Department of Neurology, Ospedale Martini, ASL Città di Torino, Turin, Italy.

158: Department of Neurology, Ospedale Maria Vittoria, ASL Città di Torino, Turin, Italy.

159: Department of Neurology, Ospedale San Giovanni Bosco, ASL Città di Torino, Turin, Italy.

160: Ospedale Humanitas Gradenigo, Turin, Italy.

161: Department of Neurology, Ospedale 'Santa Croce' di Moncalieri, ASL Torino 5, Moncalieri, Italy.

162: Department of Neurology, Ospedale Civile di Ivrea, ASL Torino 4, Ivrea, Italy.

163: Department of Neurology, Presidio Ospedaliero di Ciriè, ASL Torino 4, Ciriè, Italy.

164: Department of Neurology, Ospedale 'Degli Infermi' di Biella, ASL Biella, Ponderano, Italy.

165: Department of Neurology, Ospedale 'Sant'Andrea' di Vercelli, ASL Vercelli, Vercelli, Italy.

166: Department of Clinical and Experimental Medicine, 'Amedeo Avogadro' University of Piemonte Orientale, Novara, Italy.

167: Department of Neurology, Ospedale Civile 'Edoardo Agnelli' di Pinerolo, ALS Torino 2, Pinerolo, Italy.

168: Department of Neurology, Azienda Ospedaliera 'Santi Antonio e Biagio' di Alessandria, Alessandria, Italy.

169: Department of Neurology, Ospedale 'Santo Spirito' di Casale Monferrato, ASL Alessandria, Casale Monferrato, Italy.

170: Department of Neurology, Ospedale 'San Giacomo' di Novi Ligure, ASL Alessandria, Novi Ligure, Italy.

171: Department of Neurology, Ospedale 'Cardinal Massia' di Asti, ASL Asti, Asti, Italy.

172: Department of Neurology, Azienda Ospedaliera 'Santa Croce e Carle' di Cuneo, Cuneo, Italy.

173: Department of Neurology, Ospedale 'Maggiore Santissima Annunziata' di Savigliano, ASL Cuneo 1, Savigliano, Italy.

174: Department of Anesthesiology, Ospedale 'Maggiore Santissima Annunziata' di Savigliano, ASL Cuneo 1, Savigliano, Italy.

175: Department of Neurology, Ospedale 'Michele e Pietro Ferrero' di Verduno, ASL Cuneo 2, Verduno, Italy.

176: Department of Neurology, Ospedale 'Regina Montis Regalis' di Mondovì, ASL Cuneo 1, Italy.

177: Department of Neurology, Ospedale Regionale 'Umberto Parini' di Aosta, Aosta, Italy.

SLAGEN Consortium

Vincenzo Silani^{17,18}, Nicola Ticozzi^{17,18}, Antonia Ratti^{17,30}, Isabella Fogh¹⁴, Cinzia Tiloca¹⁷, Silvia Peverelli¹⁷, Cinzia Gellera³¹, Giuseppe Lauria Pinter^{32,33}, Franco Taroni¹⁷⁸, Viviana Pensato¹⁷⁸, Barbara Castellotti¹⁷⁸, Giacomo P. Comi^{34,18}, Stefania Corti^{34,18}, Roberto Del Bo^{34,18}, Cristina Cereda³⁵, Mauro Ceroni^{179,180}, Stella Gagliardi³⁵, Sandra D'Alfonso³⁶, Lucia Corrado³⁶, Letizia Mazzini¹⁸¹, Gianni Sorarù³⁷, Flavia Raggi³⁷, Gabriele Siciliano³⁸, Costanza Simoncini³⁸, Annalisa Lo Gerfo³⁸, Massimiliano Filosto³⁹, Maurizio Inghilleri¹⁸² & Alessandra Ferlini¹⁸³,

Affiliations

14: Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

17: Department of Neurology-Stroke Unit and Laboratory of Neuroscience, Istituto Auxologico Italiano IRCCS, Milan, Italy.

18: Department of Pathophysiology and Transplantation, “Dino Ferrari” Center, Università degli Studi di Milano, Milan, Italy.

30: Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy.

31: Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.

32: 3rd Neurology Unit, Motor Neuron Diseases Center, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy.

33: ‘L. Sacco’ Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy.

34: Neurology Unit, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

35: Genomic and Post-Genomic Center, IRCCS Mondino Foundation, Pavia, Italy.

36: Department of Health Sciences, University of Eastern Piedmont, Novara, Italy.

37: Department of Neurosciences, University of Padova, Padova, Italy.

38: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

39: Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

178: Unit of Genetics of Neurodegenerative and Metabolic Diseases, Fondazione IRCCS Istituto Neurologico ‘Carlo Besta’, Milan, Italy.

179: Unit of General Neurology, IRCCS Mondino Foundation, Pavia, Italy.

180: Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy

181: ALS Center, Department of Neurology, Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy

182: Rare Neuromuscular Diseases Centre, Department of Human Neuroscience, Sapienza University, Rome, Italy

183: Unit of Medical Genetics, Department of Medical Science, University of Ferrara, Ferrara, Italy.

SLAP Consortium

Giancarlo Logroscino⁴³, Ettore Beghi⁴², Isabella L. Simone¹⁸⁴, Bruno Passarella¹⁸⁵, Vito Guerra¹⁸⁶, Stefano Zoccolella¹⁸⁷, Cecilia Nozzoli¹⁸⁵, Ciro Mundi¹⁸⁸, Maurizio Leone¹⁸⁹, Michele Zarrelli¹⁸⁹, Filippo Tamma¹⁹⁰, Francesco Valluzzi¹⁹¹, Gianluigi Calabrese¹⁹², Giovanni Boero¹⁹³ & Augusto Rini¹⁸⁵

Affiliations

42: Laboratory of Neurological Diseases, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

43: Department of Clinical Research in Neurology, University of Bari at “Pia Fondazione Card G. Panico” Hospital, Bari, Italy.

184: Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.

185: Neurological Department, Antonio Perrino's Hospital, Brindisi, Italy.

186: National Institute of Digestive Diseases. IRCCS S. de Bellis Research Hospital, Castellana Grotte, Italy.

187: ASL Bari, San Paolo Hospital, Milan, Italy.

188: Department of Neuroscience, United Hospital of Foggia, 71100 Foggia, Italy.

189: Unit of Neurology, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.

190: Neurology Unit, Miulli Hospital, Acquaviva delle Fonti, BA, Italy.

191: Unit of Neurology, "S. Giacomo" Hospital, Bari, Italy.

192: Department of Neurology, ASL (Local Health Authority) at the "V Fazzi" hospital, 73100 Lecce, Italy.

193: Department of Neurology, ASL (Local Health Authority) at the "SS. Annunziata" hospital, Taranto, Italy.

Acknowledgments

W.v.R. is supported by funding provided by the Dutch Research Council (NWO) [VENI scheme grant 09150161810018] and Prinses Beatrix Spierfond (neuromuscular fellowship grant W.F19-03). J.J.F.A.v.V. is funded by Projectnumber W.OR20-08 (The “Repeatome” as a basis for new treatments of ALS) of the Prinses Beatrix Spierfonds. K.P.K. is supported by funding provided by the Dutch Research Council (NWO) [VIDI grant 91719350]. G.S. was supported by a PhD studentship from the Alzheimer’s Society. E.H. and J.M. were supported by Medical Research Council (MRC) grant K013807 (awarded to J.M.). mQTL SMR data analysis was undertaken using high-performance computing supported by a Medical Research Council (MRC) Clinical Infrastructure award M008924 (awarded to J.M.). French ALS patients of the Pitié-Salpêtrière hospital (Paris) have been collected with ARSla funding support. D.B. and T.R.G. received funding from Biogen and UK Medical Research Council (MRC Epidemiology Unit, MC_UU_00011/1 and MC_UU_00011/4) for this project. G.D.S. works in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol MC_UU_00011/1. D.B., E. Tsai and H.R. are employees of Biogen. J.P.R. is funded by the Canadian Institutes of Health Research (FRN 159279). A.A.K is supported by The Motor Neurone Disease Association (MNDA) and NIHR Maudsley Biomedical Research Centre. R.J.P. is supported by the Gravitation program of the Dutch Ministry of Education, Culture, and Science and the Netherlands Organization for Scientific Research (NWO; BRAINSCAPES). Project MinE Belgium was supported by a grant from IWT (n° 140935), the ALS Liga België, the National Lottery of Belgium and the KU Leuven Opening the Future Fund (awarded to P.V.D.). P.V.D holds a senior clinical investigatorship of FWO-Vlaanderen and is supported by the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders, the ALS Liga België and the KU Leuven funds “Een Hart voor ALS”, “Laeversfonds voor ALS Onderzoek” and the “Valéry Perrier Race against ALS Fund”. Several authors of this publication are members of the European Reference Network for Rare Neuromuscular Diseases (ERN-NMD). The authors are pleased to acknowledge the contribution of “Live now” Charity Foundation and Moscow ALS palliative care service for supporting patients with ALS and their families. G.A.R is supported by the Canadian Institutes of Health. Research Australia including its Ice Bucket Challenge Grant. We acknowledge funding from the National Health and Medical Research Council (NHMRC) (1078901, 1083187, 1113400, 1095215, 1121962, 1173790, Enabling Grant #402703). The Older Australian Twins Study (OATS, used for controls) acknowledges funding from the NHMRC/Australian Research Council Strategic Award (401162) and NHMRC (1405325, 1024224, 1025243, 1045325, 1085606, 568969, 1093083). OATS was facilitated through access to Twins Research Australia, a national resource supported by a NHMRC Centre of Research Excellence Grant (1079102). The Sydney Memory and Ageing Study (Sydney MAS, used for controls) has been funded by three NHMRC Program Grants (350833, 568969, and 1093083). We also acknowledge the OATS and Sydney MAS research teams: <https://cheba.unsw.edu.au/research-projects/sydney-memory-and-ageing-study>; <https://cheba.unsw.edu.au/project/older-australian-twins-study>. D.C.W. is supported by a Research Fellowship [APP1155413] from the National Health and Medical Research Council of Australia (NHMRC). The QSkin Study is supported by Grants [APP1185416, APP1073898, APP1063061] from the National Health and Medical Research Council of Australia (NHMRC). Several authors of this publication are members of the Netherlands Neuromuscular Center (NL-NMD) and the European Reference Network for rare neuromuscular diseases EURO-NMD. PJS is supported as an

NIHR Senior Investigator and by the Sheffield NIHR Biomedical Research Centre. This is in part an EU Joint Programme - Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organisations under the aegis of JPND - www.jpnd.eu (United Kingdom, Medical Research Council (MR/L501529/1; MR/R024804/1) and Economic and Social Research Council (ES/L008238/1)) and through the Motor Neurone Disease Association. This study represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. A.A-C is supported by an NIHR Senior Investigator Award. Samples used in this research were in part obtained from the UK National DNA Bank for MND Research, funded by the MND Association and the Wellcome Trust. We would like to thank people with MND and their families for their participation in this project. We acknowledge sample management undertaken by Biobanking Solutions funded by the Medical Research Council at the Centre for Integrated Genomic Medical Research, University of Manchester. L.H.v.d.B. reports grants from The Netherlands Organization for Health Research and Development (Vici scheme), grants from The European Community's Health Seventh Framework Programme (grant agreement n° 259867 (EuroMOTOR)), grants from The Netherlands Organization for Health Research and Development) the STRENGTH project, funded through the EU Joint Programme – Neurodegenerative Disease Research, JPND). This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement n° 772376 – ESORIAL). The collaboration project is co-funded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships. This study was supported by the ALS Foundation Netherlands

Author contributions

Sample ascertainment: W.v.R, R.A.A.v.d.S, M.M, A.M.D, H-J. Westeneng, G.H.P.T, N.T, J.C-K, B.N.S, M.G, S.C, S.P, K.E.M, P.J.S, J.H, R.W.O, M.S, T.M, N.B, A.J.v.d.K, A.R, C.G, G.L.P, G.P.C, C.C, D.S, S.D'A, G. Sorarù, G. Siciliano, M.F, A.P, A.C, A. Calvo, C.M, M.B, A. Canosa, M. Grassano, E.B, E.P, G.L, B.N, A.O, A.N, Y.L, M.Z, M. Gotkine, R.H.B, S.B, P.V'h, P.C, P. Couratier, S.M, V.M, F.S, J.S.M.P, A.A, R.R-G, P. Dion, J.P.R, A.C.L, J.H.W, D. Brenner, A.F, G.B, A.B, A.D, C.A.M.P, S.S-D, N.W, S.T, R. Rademakers, A. Braun, J.K, D.C.W, C.M.O, A.G.U, A.H, M.R, S. Cichon, M.M.N, P.A, B.T, A.B.S, M. Mitne Neto, R.J.C, R.A.O, M.W-P, C.L-H, V.M.v.D, J.G, A. Rödiger, N.G, A.J, T.B, E.T, B.I, B.S, O.W.W, R.S, C.A.H, C. Graff, L.B, V.F, V.D, A. Ataulina, B.R, B.K, J.Z, M.R-G, D.G, Z.S, V. Drory, M.P, I.P.B, M.C.K, R.D.H, S. Mathers, P.A.M, M.N, G.A.N, R.P, D.B.R, K.M, P.S.S, M.d.C, S. Pinto, S. Petri, A. Osmanovic, M.W, G.A.R, V.S, J. Glass, R.H. Brown, J.E.L, C.E.S, P.M.A, D.F, F.C.G, A.F.M, R.L.M, O.H, A.A-C, P.V.D, L.H.v.d.B, J.H.V, G.C, N.R, C.L, F.G, M.S.C, F.R, L.C, M.C.G, P.P, M.C, L.D, C.F, L. Tremolizzo, M.L.D, G. Bono, U.M, R.V, A. Bombaci, F.C, G.F, P.S, B. Iazzolino, L.P, P. Cugnasco, G.D.M, M.C.T, F.P, S.G, M. Barberis, L.S, S. Gentile, A.M, L.M, F.D.M, L. Corrado, A. Bertolotto, M. Gionco, D.L, E.O, D.I, R.C, P. Pignatta, M.D.M, C. Geda, D.M.P, G.G, C. Comi, C. Labate, L.R, D. Ferrandi, E.R, M.A, N.D.V, P.M, P.G, N.L, M. Dotta, A.D.S, G. Giardini, C.T, S. Peverelli, F.T, V.P, B.C, S. Corti, R.D.B, C. Cereda, M. Ceroni, L. Mazzini, F. Raggi, C.S, A.L.G, M.I, A. Ferlini, I.L.S, B.P, V.G, S.Z, C.N, C. Mundi, M.L, M. Zarrelli, F. Tamma, F.V, G. Calabrese, G. Boero & A. Rini **SNP-array genotyping:** W.v.R, R.A.A.v.d.S, A.M.D, A.S, I.F, G.B, A.B, A.D, C.A.M.P, S.S-D, N.W, L.T, W.L, A. Franke, S.R, A. Braun, J.K, D.C.W, C.M.O, A.G.U, A.H, M.R, S. Cichon, M.M.N, P.A, B.T, A.B.S, B.B, S.F, S.T.N, F.J.S, K.L.W, A.K.H, L.W, C. Curtis, G. Breen, D.F, F.C.G,

A.F.M, N.R.W, A.A-C, P.V.D, L.H.v.d.B & J.H.V **GWAS quality control:** W.v.R, R.A.A.v.d.S, M.K.B, R.R, R.L.M, N.R.W and J.H.V. **GWAS data analysis:** W.v.R, R.A.A.v.d.S, M.K.B, R.R, R.P.B, M.D, M.H, A.A.K, A.I, A.S, N.T, B.N.S, B.B, D.F, A.F.M, R.L.M, N.R.W and J.H.V. **Whole-genome sequencing:** W.v.R, R.A.A.v.d.S, P.J.H, R.A.J.Z, M.M, A.M.D, G.H.P.T, K.R.v.E, M.K, J.C-K, B.N.S, K.P.K, A.A-C, P.V.D, L.H.v.d.B and J.H.V. **WGS quality-control:** W.v.R, R.A.A.v.d.S, J.J.F.A.v.V, P.J.H, R.A.J.Z, M.M, K.P.K, P.V.D and J.H.V. **WGS rare-variant burden analyses:** W.v.R, R.A.A.v.d.S, P.J.H, R.A.J.Z, K.R.v.E, K.P.K, P.V.D and J.H.V. **WGS STR-analyses:** W.v.R, J.J.F.A.v.V, R.A.J.Z, E.D, M.A.E and J.H.V. **eQTL analyses:** W.v.R, R.A.A.v.d.S, M.K.B, N.d.K, H-J.W, O.B.B, P.D, J.M, L.F and J.H.V. **mQTL analyses:** W.v.R, M.K.B, P.J.H, R.A.J.Z, G.S, E.H, A.M.D and J.H.V. **Cross-disorder analyses:** W.v.R, R.A.A.v.d.S, M.K.B, N.d.K, H-J.W, O.B.B, P.D, E.J.N.G, M.A.v.E, R.J.P, A.F.M, N.R.W, E. Tsai, H.R, L.F and J.H.V. **MR analyses:** W.v.R, R.A.A.v.d.S, M.K.B, D.B, H.J.W, G.D.S, T.R.G, E. Tsai, H.R, and J.H.V. **Writing of the manuscript:** W.v.R, M.K.B, D.B, J.M, E. Tsai and J.H.V. **Revising the manuscript:** W.v.R, R.A.A.v.d.S, M.K.B, J.J.F.A.v.V, G.S, E.H, D.B, R.R, E.D, H.J.W, G.H.P.T, K.R.v.E, E.J.N.G, M.A.v.E, R.J.P, G.D.S, T.R.G, R.L.M, K.P.K, N.R.W, E. Tsai, H.R, L.F, L.H.v.d.B and J.H.V. **Acquired funding and supervised the study:** L.H.v.d.B and J.H.V.

Competing Interests

J.H.V has sponsored research agreements with Biogen Idec. L.H.v.d.B receives personal fees from Cytokinetics, outside the submitted work. A.A-C. has served on scientific advisory boards for Mitsubishi Tanabe Pharma, OrionPharma, Biogen Idec, Lilly, GSK, Apellis, Amylyx, and Wave Therapeutics. A.C. serves on scientific advisory boards for Mitsubishi Tanabe, Roche, Biogen, Denali, and Cytokinetics.